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Many diseases are caused by aberrant inflammation. Novel drug strategies are transitioning 
from global suppression and single-target inhibition to fine tuning the immune response by 
modifying several key pathways in order to minimize tissue injury. Recently, classes of 
pleiotropic, electrophilic lipids (mainly nitroalkenes and α, β-unsaturated ketones), are emerging 
as prominent immunomodulators that both dampen inflammation and initiate cytoprotective 
responses.  Electrophilic lipids alkylate nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-ĸB) causing a decrease in inflammation. Furthermore, kelch-like ECH-associated 
protein 1 (Keap1) is also alkylated by electrophilic lipids, causing the release of nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) and the activation of hundreds of genes involved in repairing 
and preventing cellular injury.  
Moreover, endogenous lipid mediators such as Lipoxin A4 (LXA4) have successfully 
limited tissue injury in animal models of sepsis, acute lung injury, and asthma. The primary 
metabolite of LXA4, 15-oxo-LXA4, is electrophilic and its role in immune responses is 
understudied. Herein, I demonstrate that 15-oxo-LXA4 acts in a similar manner to other 
electrophilic lipids and limits LPS-induced inflammatory responses in murine macrophages. These 
data suggest electrophilic metabolites of endogenous lipid mediators such as LXA4 may be 
partially responsible for their anti-inflammatory and cytoprotective actions. 
Nitroalkenes alkylate NF-ĸB and Keap1, resulting in dampened inflammatory responses 
and active tissue repair. In fact, Nitro-Oleic Acid (NO2-OA) is currently in clinical trials for focal 
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segmental glomerulosclerosis, asthma and pulmonary hypertension. Much of the preclinical 
research for nitroalkenes has been carried out in epithelial, endothelial, or macrophages so their 
effect on dendritic cell function is largely unknown. The data provided within suggest that NO2-
OA limits DC activation. These changes are consistent with other electrophilic lipids and suggest 
a common role in modifying immune responses.  
Lastly, I tested the efficacy of NO2-OA in treating influenza-induced lung injury in mice. 
Survival increased compared to vehicle controls and pro-inflammatory cytokine production was 
decreased. These results demonstrate the potential of NO2-OA to improve outcomes of severe viral 
infection, characterized by aberrant inflammation. Further research on NO2-OA, 15-oxo-LXA4 
and other electrophiles will enhance the knowledge of these agents and inform future clinical trials 
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1.0 Introduction 
1.1 Inflammation and Injury 
Inflammation is an essential response to tissue injury and infection. A myriad of external 
stimuli such as air pollution, viruses, and trauma can incite an inflammatory response. 
Furthermore, internal irritants such as stress, atherosclerosis, and changes in metabolism (e.g. type 
II diabetes) will initiate similar actions. The cardinal signs of inflammation include redness, pain, 
heat, swelling, and loss of function. These symptoms are caused by the production of cytokines 
and chemokines that activate the local environment and recruit leukocytes to clear the insult. All 
symptoms eventually decrease as the infection or injury is cleared; however, the strength and 
duration of the response can vary – sometimes in a negative manner. Excessive responses can 
result in acute episodes that cause significant bystander tissue damage while chronic responses 
skew the normal immune response to an altered, malignant state [1, 2]. Therefore, much of our 
health depends on the well-orchestrated and near-perfect collaboration between all aspects of the 
immune response [3-6]. In fact, immunity involves every aspect of cellular signaling from growth, 
proliferation, and metabolism to programmed cell death, making drug discovery and 
pharmacological examination of novel therapeutics difficult. A better understanding of how 
inflammation is controlled will likely lead to novel therapeutics for hundreds of diseases and it is 




1.1.1 Inflammatory Signaling 
Inflammation begins with the detection of cellular injury (e.g. xenobiotic toxicity, trauma), 
infection, internal stress from metabolic imbalances, protein overload (endoplasmic reticulum 
stress), or genome instability [4, 6]. Cellular damage, infection, and other noxious stimuli are 
detected by damage-associated or pathogen-associated molecular patterns (DAMPs and PAMPs) 
by a variety of receptors on the surface of many cell types, including immune cells. For example, 
airway epithelial cells and antigen-presenting cells (APCs) express toll like receptors (TLRs) that 
bind PAMPs such as lipopolysaccharide (LPS), cytosolic DNA, and double-stranded RNA [7-10]. 
Many DAMPs are released during cell death and include uric acid, ATP, extracellular DNA, 
oxidized phospholipids (oxPLs), and a variety of different proteins such as interleukin (IL)-33 [1, 
11-13]. Together with a host of transcription factors and intracellular signaling cascades, these 
detectors will initiate the inflammatory response by alerting innate immune cells.  
          After detecting cellular damage and other noxious stimuli, cells will produce a host of pro-
inflammatory mediators including lipid mediators, cytokines, and chemokines. This is done by 
activating transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-ĸB) downstream of pattern recognition receptors and their associated kinases (e.g. 
MyD88 for TLR4). In addition to the transcription of pro-inflammatory genes, cells will be 
mobilized for changes in proliferation, metabolism, and migration depending on the acting 
stimulus [14, 15]. This simplified scenario will result in the production of cytokines like interleukin 
(IL)-12, IL6, monocyte chemoattractant protein 1 (MCP1), and tumor necrosis factor alpha 
(TNFα). Moreover, enzymes such as cyclooxygenase (COX)-2 and inducible nitric oxide synthase 
(NOS2) will be induced and begin synthesizing their products (i.e. prostaglandins and nitric oxide). 
These actions will attract neutrophils, activate resident macrophages and dendritic cells (DCs), and 
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alert nearby monocytes to differentiate into a myriad of effector cells. Then, these innate cells will 
converge to eliminate the damaging stimuli as well as initiate adaptive immune responses in the 
event the same stimulus is seen again. Under normal conditions, these responses will clear the 
insult and initiate cellular repair mechanisms that return tissues to homeostasis. Until inflammation 
is resolved, the cycle of stimulation, cellular activation, production of cytokines, reactive oxygen 
and nitrogen species, and lipid mediators will continue indefinitely (Fig 1). 
Figure 1: Positive feedback loop of inflammation 
 A stimulus (DAMP or PAMP) will intiate a signal relay (e.g. NF-ĸB), usually involving 
phosphorylation cascades, that will alter  the expression of hundreds if not, thousands of genes 
within the cell in order to respond to injury or stress. A response consisting of free radicatl 
generation, cytokine production, and cellular recruitment will insue and continue until 
inflammation resolves; otherwise, irreversible tissue damage will result.  
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1.1.2 Aberrant Inflammation 
When inflammation fails to resolve, damage to cells and tissues occurs through excessive 
generation of reactive oxygen and nitrogen species, cell death, and the sustained recruitment of 
leukocytes and cytokine production [16, 17]. For example, viral-induced acute lung injury can 
result in acute respiratory distress syndrome due to an exuberant host response [18]. In this case, 
neutrophils and dendritic cells become pathogenic by generating massive amounts of free radical 
species that promote tissue injury [19-22]. In multiple sclerosis (MS), DCs activate T lymphocytes 
that cause myelin sheath degeneration [23, 24]. The pathogenesis to MS is closely linked to the 
amplification of effector T cells and the sustained production of pro-inflammatory cytokines (e.g. 
IL12, IL23, IL6, interferon [IFN]γ) from DCs [23, 24]. Most inflammatory diseases – acute, 
chronic, and autoimmune – are linked with the prolonged and aberrant production of cytokines 
and a sustained presence of immune cells. Therefore, novel therapeutics are targeting macrophages 
and dendritic cells for their central role in initiating both innate and adaptive immunity. 
1.1.3 Key regulators of immunity 
Cytokine and chemokine production, in addition to the release of lipid mediators like 
prostaglandins and pro-resolving mediators, activate and instruct immune cells. Mainly, 
neutrophils, macrophages, and DCs will be the first to respond to injury or infection, depending 
on the nature and location of the insult. These cells can be residents of the tissue (e.g. Alveolar 
macrophages – lung, Langerhans DCs – skin) or circulate within the bloodstream until chemokines 
induce their migration. As more cells are needed, monocytes or other precursors from the 
bloodstream or bone marrow can differentiate into more specialized cell subsets, depending on the 
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needs of the immune response – all defined by tissue type, local environment, duration, and 
strength of signals received by each individual cell. Both macrophages and DCs are absolutely 
essential for initiating immune responses and activating adaptive immunity by presenting antigen 
to T and B lymphocytes.  
1.1.3.1 Dendritic Cells and Macrophages 
 
DCs are specialized cells defined by their ability to sample the environment for antigens 
and initiate immune responses. Activated DCs are programmed to rapidly react and regulate the 
immune response according to the given stimulus [25-27]. Upon ligation of TLR ligands, DCs will 
alter their metabolism in order to accommodate the rapid expansion of membranes, cytokine 
production, the growing ATP demand, and reducing factors such as NADPH [28-31]. During and 
after metabolic reprogramming, DCs will continue to generate cytokines and chemokines (e.g. 
IL6, IL12, IL23, IL15) that recruit and activate natural killer cells, surrounding macrophages, 
neutrophils, and lymphocytes. Some DCs will migrate to nearby lymph nodes to initiate adaptive 
immunity by presenting antigen to T and B cells – bridging all aspects of the immune response 
[32-34]. Because of their essential role in innate and adaptive immunity, DCs are becoming targets 
for novel therapeutics that aim to modulate aberrant immune responses [35]. In fact, there are 
instances of acute and chronic inflammation where limiting DC function is effective in minimizing 
tissue damage caused by excessive cytokine production and free radical production [19, 36-38]. 
          Macrophages, like DCs, are often positioned in tissues where they can quickly respond to 
pathogens or injury. For example, alveolar macrophages of the lung will become activated upon 
viral infection or inhalation of air pollutants. These cells will also utilize TLRs and other pattern 
recognition receptors in order to instruct intracellular signaling cascades that induce or repress 
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hundreds of genes. Cytokine production will alert nearby cells and macrophages will begin 
phagocytosing damaged cells and/or pathogens, while DCs are activating T and B lymphocytes 
[39-42]. The function and method of activation for DCs and macrophages are very similar, in fact, 
both undergo aerobic glycolysis after LPS administration and produce cytokines and chemokines 
to initiate immunity. Furthermore, they possess similar surface markers (e.g. CD11c, CD11b, 
MHCII) and are a heterogeneous population when cultured in vitro [43-46]. Therefore, 
therapeutics designed for one or the other may impact both populations, making understanding 
macrophage and DC pharmacodynamics during treatment essential.  
1.1.3.2 Immunometabolism 
 
Metabolism plays a major role in the regulation of immunity [47-49]. As tissues respond 
to damage and pathogens, energy requirements are shifted to meet the demanding use of lipids, 
proteins, nucleotides, and reducing factors (e.g. NADPH) by cells. Immune cells undergo rapid 
growth and proliferation, in addition to producing RS, cytokines, and lipid mediators, requiring 
massive generation of cellular building blocks [50-52]. Similar to cancer cells, many immune cells 
will enter aerobic glycolysis to meet their new energy quota [49]. In general, cells will shunt 
glucose into glycolysis despite having enough oxygen for the TCA cycle and oxidative 
phosphorylation. However, there are tiers and gradients to this response and recent data suggests 
different subsets of immune cells will have optimized and disparate metabolic states [53-58]. For 
example, inflammatory T cell phenotypes, TH17 and TH1, undergo aerobic glycolysis whereas, 
TH2 and TREG (allergic and anti-inflammatory phenotypes) will rely on oxidative 
phosphorylation and fatty acid catabolism [53, 59].  
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          Furthermore, pro-inflammatory macrophages (M1) can be distinguished from their 
reparative counterparts (M2) by their metabolic patterns. Much like TH1 and TH17 cells, M1 
macrophages will utilize glycolysis more than oxidative phosphorylation [55, 60]. A plethora of 
studies have demonstrated how manipulating proteins that regulate metabolism can augment 
immune responses. Dimethyl fumarate (DMF), a synthetic analog of the electrophilic metabolite, 
fumarate, can alkylate GAPDH and inhibiting IFN signaling in DCs [61, 62]. Targeting molecular 
target of rapamycin (mTOR), hypoxia inducible factor (HIF) α, pyruvate kinase, or succinate 
dehydrogenase all affect T cells, DC, and/or macrophages [55, 63-76]. Immunometabolism plays 
a key role in inflammation and has been reviewed extensively [48-51, 54, 56, 58, 59, 70, 77]. 
Hence, novel therapeutics based on metabolism are being designed to combat inflammatory 
diseases involving DCs, macrophages, and T lymphocytes.  
1.2 Returning to homeostasis after inflammation 
It is becoming clear that repair mechanisms and the resolution of inflammation begin not 
long after the innate response begins [78-83]. In fact, many transcription factors meant for cellular 
recovery are induced by the same proteins (e.g. NF-ĸB) that initiated the inflammatory response. 
For example, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is activated when reactive species 
(RS), such as superoxide and nitric oxide (produced from NAPDH oxidases [NOX enzymes] and 
NOS2 - both induced by NF-ĸB), oxidize KELCH-like associated protein 1 (KEAP1), and is 
allowed to enter the nucleus and bind to promotors with antioxidant response elements (AREs) in 
DNA [84, 85]. After Nrf2 binds to an ARE, hundreds of genes are activated that result in the 
production of antioxidants and other cellular-repair enzymes [86]. NF-ĸB also initiates the 
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production of IL-10 and tissue growth factor (TGF) β as well as induces COX and lipoxygenase 
(LOX) enzymes that oxidize arachidonic acid and other polyunsaturated lipids (e.g. 
docosahexaenoic acid), resulting in several pro-resolving lipid mediators (e.g. Lipoxin A4) – all of 
which aid in returning cells to homeostasis [87-89]. Hence, complete inhibition of NF-ĸB would 
result in the cessation of pro-inflammatory lipids such as prostaglandins and leukotrienes, as well 
as the anti-inflammatory mediators. Therefore, total suppression of the immune response may 
result in ineffective clearing of potential stimuli, perturbation of normal homeostatic functions of 
cell signaling pathways, or inhibition of resolution itself – all of which may contribute to chronic 
malformations of physiology. 
1.2.1 Nrf2 signaling and inflammation 
The Nrf2 signaling pathway plays a critical role in protecting cells from injury, activating 
antioxidant defenses, and detoxifying toxins and xenobiotics [86, 90, 91]. Under homeostatic 
conditions, Nrf2 is bound to Keap1 in the cytoplasm, ubiquinated, and marked for degradation 
[84]. After encountering certain stimuli (e.g. electrophile formation, oxidative stress), cysteines 
within Keap1 are oxidized, Nrf2 translocates to the nucleus, and binds to AREs in hundreds of 
genes (Fig 2) [84, 85, 90-92]. Genes activated represent phase II enzymes involved in the 
catabolism of xenobiotics,  such as heme oxygenase 1 (HO1) and NAD(P)H quinone 
oxidoreductase 1 (NQO1), glutathione metabolism (e.g. glutamyl-cysteinyl ligase modifier subunit 
- GCLM), and antioxidant enzymes (e.g. catalase) [86]. All of these changes function to restore 
the cell to homeostasis and minimize the collateral damage caused by the original stimulus. 
There is growing evidence suggesting Nrf2 plays a key role in regulating inflammation. It 
has been demonstrated that Nrf2 and NF-ĸB communicate and regulate each other during immune 
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responses [93, 94]. Furthermore, modulation of Nrf2 signaling can increase or decrease damage 
done in models of inflammation including influenza infection, sepsis, MS, and asthma [93, 95-99]. 
Nrf2 activation can limit pro-inflammatory cytokine production, modulate central metabolism, and 
alter several key regulatory modules within the cell (e.g. NF-ĸB) – making Nrf2 an important 
immunomodulator [100-104].  
1.2.2 Inhibition of NF-ĸB 
NF-ĸB is a central regulator of not only inflammation but cellular growth and survival as 
well [88]. NF-ĸB generally consists of a dimer of the p65 and p50 subunits (RelA and RelB) and 
held together in the cytoplasm by IĸB [88]. Signal transduction between TLRs and NF-ĸB is 
largely controlled by protein cascades mediated by kinases and adaptor proteins that relay their 
message via phosphorylation (Fig 2). Upon activation, a phosphorylation cascade occurs and NF-
ĸB translocates to the nucleus where it binds to the promotor region (ĸB) of hundreds, if not 
thousands of genes, altering their transcription [15, 105-109]. After pathogen or injury detection 
(e.g. TLR signaling), the inhibitor of NF-κB (IκB) kinase (IKK) is phosphorylated leading to the 
phosphorylation and subsequent degradation of IĸB [110]. After IĸB is degraded, p65/p50 dimers 
are free to enter the nucleus and activate inflammatory gene expression. Non-canonical NF-ĸB 
signaling can consist of p50/p50 dimers, and p50/p52 – all with varying effects on inflammation 
[111]. In regards to inflammation, NF-ĸB activation will lead to increased expression of Nos2, 
Cox2 Il6, Tnfa, Il1b, and other primary inflammatory executors. Despite the pathway being 
10 
1.3 Formation and signaling of electrophilic lipids 
Two main classes of endogenously-produced electrophilic lipids are the α, β-unsaturated 
ketones and nitroalkenes (Fig 3). Both are formed either through enzymatic oxidation and 
reduction reactions or free-radical induced oxidation and nitration reactions [114-116]. Once 
Figure 2: Simplified model of NF-κB and Nrf2 signaling 
DAMPs (such as oxidized phospholipids, oxPL) and PAMPs (e.g. viruses) will bind TLRs and 
intiate a signaling cascade that leads to NF-ĸB activation (A). Oxidative stress and other 
components of inflammation will lead to Keap1 oxidation, Nrf2 release and activation (B). These 
factors, among others, will ensure a well-orchestrated response that minimizes bystander damage 
and maximizes injury clearance.  
immensely complex and multilayered, it has become a primary target in developing anti-
inflammatory and immunomodulatory therapeutics [15, 109, 112, 113].  
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formed, the electrophilic moiety rapidly alkylates nearby nucleophiles. Many key regulatory 
proteins utilize cysteine residues to carry out their function. The thiol groups (especially 
deprotonated, thiolate anion) within these proteins will form a covalent, Michael adduct with 
electrophilic lipids (Fig 4). After alkylation, protein function may be unchanged, activated, or 
inhibited, depending on cellular conditions – culminating in major cellular changes. Many 
electrophilic lipid mediators are formed during inflammation and play a role in maintaining 
cellular homeostasis and dampening tissue injury. 
Electrophiles (electron poor) contain electron-withdrawing groups (e.g. nitro-, carbonyls, 
cyano-) that render specific carbons more capable of forming a Michael adduct with nucleophilic 
(electron rich) functional groups such as thiols. The covalent, Michael adduct can be reversible 
when “soft” electrophiles modify “soft” nucleophiles; however, hard electrophiles and hard 
nucleophiles will typically form irreversible covalent adducts – based on electronegativity, steric 
hindrance, and other chemical factors [117-119]. Only recently, have soft electrophiles been 
appreciated for their reversible, and often anti-inflammatory properties because drug developers 
were concerned mostly with hard electrophiles and their toxicity due to the formation of 
irreversible adducts [118, 120]. Many hard electrophiles alkylate nucleotide bases or completely 
inactivate cell signaling pathways. For example, terminal aldehydes (i.e. formaldehyde) are 
extremely toxic because they alkylate many proteins and DNA [121]. Most biological 
macromolecules contain nucleophilic moieties with the potential to donate electrons to 
electrophiles, forming covalent bonds. These include but are not limited to thiol (especially 
deprotonated thiolate anion) groups present within cysteines; the imidazole ring within histidine; 
and amine groups of lysine and nucleotide bases. Hard electrophiles are usually charged and bind 
hard nucleophiles while soft electrophiles typically have delocalized charges and bind soft 
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electrophiles [122]. Therefore, soft electrophiles can modify cell signaling pathways without 
complete inactivation, making them useful tools to dampen multiple pathways at once 
(polypharmacology) without the toxic effects of a complete loss in activity [123].  
1.3.1 Endogenous electrophile formation 
Although much is known about the enzymatic and non-enzymatic oxidation of unsaturated 
lipids, lipid nitration is less understood [124-129]. The structural characteristics of the unsaturated 
lipid define the reaction products and their formation is largely dependent on the differing chemical 
activities between bis-allylic and conjugated diene systems. Two different mechanisms have been 
proposed for the nitration of polyunsaturated bis-allylic lipids [130]. In short, the nitro-group can 
either be added directly or indirectly following oxidation and double bond rearrangement – both 
eventually leading to an electrophilic, nitroalkene moiety. α,β-unsaturated ketones can be formed 
through enzymatic reactions (e.g. oxidation of 15-hydroxyeicosatetraenoic acid [15-HETE] into 
15-oxoETE via 15-prostaglandin dehydrogenase [15-PGDH]) or free-radical induced events such 
as lipid peroxidation (Fig 3) [128, 129, 131]. Inflammation induces NOS2 and NOX enzymes that 
produce nitric oxide (.NO) and superoxide (O2.-) that, after several free radical-based reactions, 
form the nitrogen dioxide and hydroxyl radicals (Figure 3). These radicals will nitrate or oxidize 
double bonds that are electron poor, creating electrophilic nitroalkenes and oxidized fatty acids. 
Hydroxy fatty acids can then be reduced via dehydrogenases (e.g. 15-PGDH) to form electrophilic, 
α, β – unsaturated ketones. Alternatively, hydroxy fatty acids, like the cyclopentenones, are formed 
enzymatically via COX2 or LOX and then reduced into electrophilic α, β-unsaturated ketones via 




Figure 3: Electrophilic lipid formation  
Both nitroalkenes and α,β-unsaturated ketones are formed during inflammation when unsaturated 
fatty acids react with reactive oxygen and nitrogen species formed from NOS2 and NOX enzymes. 
Electrophilic α,β-unsaturated ketones are also formed via enzyme-catalyzed (e.g. LOX, COX2) 
reactions.  
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1.3.2 Electrophilic lipid signaling 
There is a myriad of electrophiles, formed endogenously, that differ in reactivity, 
reversibility of covalent reactions, concentration, and half-life. Many are toxic, including 
formaldehyde, acetaldehyde, hydroxynonenal (HNE), and malondialdehyde because they form 
irreversible protein and DNA adducts that accumulate in the cell over time. Some are viewed as 
biomarkers of oxidative stress, such as HNE and malondialdehyde, although their signaling role is 
not exactly clear. Finally, in recent years anti-inflammatory and cytoprotective electrophilic lipids 
are garnering interest for treating chronic and acute diseases of inflammation. These electrophiles 
include nitro-lipids and α, β-unsaturated ketones that, unlike the above hard electrophiles, can 
reversibly alkylate cysteines in key regulatory proteins, through Michael adduct formation (Fig 4). 




1.3.2.1 Limiting Inflammation 
 
NF-ĸB is a central regulator of inflammation and can react to and initiate a variety of 
oxidative signaling events [14, 132]. Furthermore, NF-ĸB signals by forming dimers and 
translocating to the nucleus, binding ĸB promoter regions, ultimately leading to the activation of 
hundreds of genes – all of this activity is affected by RS and, in some cases, inhibited by 
electrophilic lipids. The canonical NF-ĸB pathway is initiated when IKK phosphorylates IĸB, 
leading to its degradation and release of the p65/p50 dimer to the nucleus[88]. Nitroalkenes bind 
Cys179 of IKKβ, Cys62 of p50 and Cys38 and Cys105 of p65[133, 134]. Due to alkylation, nuclear 
translocation of the p65/p50 dimer is reduced along with the expression of pro-inflammatory genes 
Figure 4: Michael Adduct Formation 
Electrophilic lipids alkylate nucleophilic cysteine residues on proteins. 
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including IL6, MCP1, NOS2, COX2, and TNFα – shown in multiple in vitro and in vivo studies 
during the past decade [133, 135-140].  
Several α, β-unsaturated ketones have also shown a remarkable ability to dampen 
inflammation through the inhibition of NF-ĸB, including prostaglandin metabolite, 15-deoxy-Δ-
12,14-prostaglandin J2 (15d-PGJ2), and metabolites of polyunsaturated lipids (e.g. 15-oxoETE). 
Several groups demonstrated 15d-PGJ2, an electrophilic metabolite of PGJ2, Inhibits multiple steps 
along the NF-ĸB pathway [113, 141]. Rossi, et al. showed that Cys179 of IKKβ forms a Michael 
adduct with 15d-PGJ2, leading to decreased IKKβ activation and consequently, NF-ĸB activation 
[141]. Straus, et al. similarly demonstrated 15d-PGJ2 alkylates Cys38 of p65, and Cernuda-
Morollon, et al. showed Cys62 of the p50 subunit is also alkylated by 15d-PGJ2, resulting in 
decreased inflammation [113, 142]. Lastly, oxidized products of polyunsaturated lipids are often 
electrophilic and possess an ability to inhibit NF-ĸB signaling. 15-HETE is oxidized to 15-
oxoETE, an electrophilic lipid, with the ability to dampen several aspects of inflammation 
including IL6, MCP1, and TNFα production – likely through inhibition of p65/p50 translocation 
[143, 144]. Together, these examples provide a strong argument for NF-ĸB being a common target 
for a wide class of electrophilic lipids, despite their assumed promiscuity in non-specifically 
binding proteins with available cysteines.  
  
1.3.2.2 Protecting cell and tissue integrity 
 
In addition to NF-ĸB inhibition, many electrophilic lipids are known to activate the Nrf2 
antioxidant pathway. Nitroalkenes alkylate Cys151, Cys273, and Cys288 of Keap1, causing Nrf2 
translocation to the nucleus, binding of the ARE, and activation of hundreds of antioxidant and 
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cytoprotective genes including HO1, GCLM, NQO1, and glutathione S-transferase (GST) [134, 
145, 146]. Moreover, 15d-PGJ2 can covalently modify Keap1 and activate the Nrf2 pathway [147-
149]. In fact, there is a review describing strategies to use nitroalkenes or 15d-PGJ2 to ameliorate 
inflammatory disorders due to their ability to protect cells via the Nrf2 pathway [147]. 
Electrophilic metabolites of unsaturated lipids such as 15-oxoETE also activate Nrf2 in addition 
to their ability to inhibit the NF-ĸB pathway [143, 144]. Nrf2, like NF-ĸB, seems to be a common 
target of electrophilic lipids with the end result being cytoprotection and dampened inflammation. 
1.3.2.3 Inactivation of STING signaling and other pathways 
 
In a recent article, myself and colleagues from Denmark, demonstrated that nitroalkenes 
can alkylate stimulator of IFN genes (STING), inhibiting its dimer formation, and ultimately IFN 
response factor (IRF) 3 activation [115]. STING detects pathogen DNA/RNA intracellular and 
initiates IFN responses [150-153]. Covalent modification of Cys88 and Cys91 within STING, 
disallow palmitoylation and clustering. Without palmitoylation, STING does not signal 
appropriately and is unable to fully activate IRF3, leading to diminishing production of IFN as 
well as other pro-inflammatory cytokines. Furthermore, nitroalkenes are reported to bind 
peroxisome-proliferated activator receptor (PPAR) γ to activate anti-inflammatory programs, 
initiate heat shock response, inactivate xanthine oxidase, and alter mitogen-activated protein 
kinase (MAPK) signaling – all of these responses potentially play a role in the cumulative anti-
inflammatory and cytoprotective effects of nitroalkenes [116, 154-157].   
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1.4 Therapeutic potential of electrophiles for inflammatory disorders 
The ability of several classes of electrophiles to alter several branches of immunity (e.g. 
Nrf2 activation and NF-ĸB) are making the case that they are efficient immunomodulators and can 
play a role in mitigating inflammatory diseases. For example, DMF was recently approved for the 
treatment of MS (Tecfidera®) and NO2-OA (CXA-10), a nitroalkene, is in phase II clinical trials 
for pulmonary arterial hypertension, asthma, and focal segmented glomerulonephritis (PRIMEx – 
NCT03449524, FIRSTx – NCT03422510, ALMA – NCT03762395). Both maintain cellular 
homeostasis and limit the damaging effects of inflammation. Moreover, other natural electrophiles 
such as curcumin and sulforaphane (SFN) found in spices and cruciferous vegetables, respectfully, 
are excellent Nrf2 activators and have been shown to limit tissue damage in several models of 
inflammation [158-160]. Most importantly, many of these electrophilic entities have great toxicity 
profiles in addition to their profound anti-inflammatory and cytoprotective effects.  
1.4.1 Nitroalkenes 
 
The nitroalkenes (e.g. NO2-OA) are an emerging class of electrophilic lipids showing 
promise in both pre-clinical animal models and phase II human studies (PRIMEx – pulmonary 
hypertension, FIRSTx – focal segmental glomerulosclerosis, ALMA – asthma) [134, 161]. 
Nitroalkenes actively promote resolution through Nrf2 activation and limit inflammation through 
a variety of mechanisms including NF-ĸB inhibition [116].  Cell culture studies have shown that 
NO2-OA alkylates Cys273 and Cys288 of Keap1, making it an efficient Nrf2 activator [145]. NO2-
OA can form covalent Michael adducts with p65 (Cys38, Cys105) and IKKβ (Cys179) – leading 
to a limitation in NF-ĸB function [133, 140]. Recently, myself and others showed that nitroalkenes 
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alkylate Cys88 and Cys91 of STING, inhibiting its palmitoylation and the downstream production 
of IFN [115]. Furthermore, researchers have demonstrated nitroalkenes activate PPARγ, initiate 
heat shock signaling, and inhibit xanthine oxidase – all with the potential of having profound 
effects in immunity [116, 154, 155]. Therefore, NO2-OA and other nitroalkenes directly alter 
immune responses by alkylating cysteines on key regulatory proteins. 
Over a decade of in vitro and in vivo models have illustrated the potent anti-inflammatory 
and cytoprotective responses of nitroalkenes. NO2-OA was effective in reducing cellular 
proliferation and tumor growth in a mouse model of triple negative breast cancer [133]. NO2-OA 
and NO2-cLA (another electrophilic nitroalkene) inhibited phosphorylation and dimerization of 
IRF3, leading to a significant depression in IFN production in bone marrow derived macrophages, 
THP1 human monocytes, and  human, STING-associated vasculopathy with onset in infancy 
(SAVI) fibroblasts (pathogenesis due to excessive IFN production) [115]. Furthermore, 
nitroalkenes limit inflammation in several models of metabolic syndrome and fatty liver disease – 
including mouse models of non-alcoholic fatty liver disease and atherosclerosis [162, 163].  
1.4.2 α,β-unsaturated ketones 
 
Many unsaturated lipids formed during inflammation (e.g. prostaglandins) or derived from 
the diet (e.g. DHA, EPA) can be metabolized into electrophilic lipids [164]. Lipoxin A4, a pro-
resolving lipid mediator derived from AA during inflammation, is oxidized into 15-oxo-LXA4, an 
electrophilic αβ-unsaturated ketone, by 15-PGDH [165]. 15-oxoETE is formed from the oxidation 
of 15-HETE and 15d-PGJ2 is formed from AA oxidation into PGD2 and the eventual oxidation 
and dehydration of its metabolite, PGJ2 [143, 144, 148]. All of the above electrophilic lipids (with 
15-oxoLXA4 described in this thesis) activate Nrf2 and inhibit NF-ĸB signaling and how similar 
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effects to DMF and the nitroalkenes in limiting inflammation. 15-oxoETE limited LPS-induced 
inflammation in RAW cells (murine macrophages) in addition to PMA-induced activation of 
THP1 (human monocyte cell line) [143, 144]. 15d-PGJ2 alkylates the p65 and p50 subunit of NF-
ĸB, directly inhibits IĸB, and covalently modifies Keap1 – all culminating in Nrf2 activation and 
multi-target inhibition of inflammation [113, 142, 148, 149]. 
DMF is a 6 carbon, α,β-unsaturated ketone approved for the treatment of MS (Tecfidera) 
[166, 167]. Studies have shown DMF can inhibit several aspects of the inflammatory response in 
a variety of different cells, including DCs, macrophages, and T cells. Due to DMF’s electrophilic 
nature, much of its intracellular effects are attributed to alkylating cysteine residues on key 
regulatory proteins [168]. DMF inhibits NF-ĸB by forming a covalent Michael adduct with Cys38 
of the p65 subunit, resulting in decreased expression of TNFα and MCP1 and inhibition of cancer 
cell growth [112]. Furthermore, DMF has been shown to alkylate Cys151, Cys273, and Cys288 
on Keap1 – all of which would allow Nrf2 nuclear translocation and the activation of over a 
hundred antioxidant and cytoprotective genes [169]. Mitigation of MS pathogenesis by DMF is 
most likely caused from a combination of activating Nrf2, inhibiting NF-ĸB, modulating 
metabolism, and other, yet to be discovered pathways. New studies have confirmed Nrf2 activation 
when DMF is administered to mice in an experimental autoimmune encephalomyelitis model of 
MS [170]. 
From in vitro and in vivo pre-clinical studies to phase II clinical trials and FDA-approved 
therapeutics, electrophiles are becoming prominent agents in treating inflammatory diseases. It is 
becoming clear that both nitroalkenes and α, β-unsaturated ketones modify macrophages and DCs 
by alkylating key regulatory proteins such as NF-ĸB and Keap1, resulting in global changes in 
inflammation, metabolism, and cellular repair pathways. Future research needs to better 
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characterize how electrophilic lipids are formed endogenously in various states of inflammation, 
how they signal in immune cell subsets, and evaluate the therapeutic potential of these species in 
disease models.   
1.5 Hypothesis and aims 
Inflammation, although necessary, is a critical component in a variety of disease states 
including, cancer, acute crises (e.g. acute respiratory distress syndrome [ARDS]), chronic, and 
autoimmune disorders. Classic treatments for inflammation are either suppressive (steroids) or 
symptomatic (non-steroidal anti-inflammatory drugs [NSAIDS]). Recent trials have evaluated a 
variety of small molecule and monoclonal antibody-based, targeted therapies that have shown 
modest success but also many side effects. Electrophilic lipids are an emerging class of 
immunomodulating agents that can hit multiple targets of inflammation and promote tissue repair 
with minimal side effects (Fig 5). My thesis evaluates three separate hypotheses, adding 
importance to electrophilic lipids in immunity.  
 First, electrophilic metabolites of pro-resolving lipid mediators are active and play a role 
in mitigating aspects of inflammation (Chapter 3). The aims of this chapter are 1) demonstrate 15-
oxo-LXA4, the primary metabolite of Lipoxin A4 is electrophilic; 2) characterize the ability of 15-
oxo-LXA4 to dampen LPS-induced inflammation and activate Nrf2-regulated cytoprotective 
responses; and 3) show these actions are independent of canonical, G-protein coupled receptor 
(GPCR)-dependent, Lipoxin A4 signaling. These aims are carried out with a common, murine 
macrophage model using LPS as the inflammatory stimuli. PCR, western blot, ELISA, and LC/MS 
are used to evaluate each aim. 
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 Second, electrophilic lipids alter DC function (Chapter 4). The aims of this chapter are 1) 
examine the effects of NO2-OA on DC activation and surface marker phenotype; 2) demonstrate 
the impact of NO2-OA on cytokine production in LPS-activated DCs; and 3) characterize the 
mechanism of action for nitroalkenes in DCs. A combination of flow cytometry, ELISA, and 
western blotting was used to carry out this project with a simple, murine bone-marrow derived DC 
model. 
Finally, electrophilic lipids will mitigate influenza-induced, acute lung injury by 
dampening inflammation (Chapter 5). The aims of this chapter are to 1) test the efficacy of NO2-
OA in a murine model of severe influenza infection, 2) understand the impact of NO2-OA 
administration on cytokine production, and 3) characterize changes in leukocyte recruitment to the 
lung during infection. Influenza A virus (H1N1 – Puerto Rico/08/1934) was used to infect mice 
and NO2-OA was delivered by oral gavage. Weight loss was recorded and used to determine 















Figure 5: Electrophilic lipid modify key proteins in immunity 
Nitroalkenes and α,β-unsaturated ketones activate Nrf2 and inhibit NF-
ĸB – altering immunity. The main mechanism of action for electrophilic 
lipids is protein alkylation (Michael adduct formation). 
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2.0 Materials and Methods 
2.1 Cells and Reagents 
RAW 264.7 (ATCC) murine macrophages grown in DMEM (10% FBS) were used for in 
vitro macrophage studies. LPS was from Sigma (Cat# L4391, Lot 067M4036V). Lipoxin A4 was 
purchased from Cayman Chemical Company (#90410) and 15-oxo-LXA4 was synthesized as a 
methyl ester (15-oxo-LXA4-ME) for cellular delivery as described recently [171]. The formyl 
peptide receptor (FPR) 2 antagonist, WRW4 was purchased from Tocris (#2262). Madin-Darby 
Canine Kidney (MDCK, ATCC) were provided by Seema Lakdawala, Ph.D. and 
Influenza/A/Puerto Rico/08/1934 (PR8) was purchased from the ATCC. Glycerol Trioleate was 
purchased from Sigma and used as the vehicle for oral delivery of NO2-OA.  
2.2 Bone marrow-derived dendritic cells (BMDCs) 
All mouse experiments were in accordance with protocols approved by the University of 
Pittsburgh IACUC committee. Femurs from male, C57BL/6 (Jackson, 8-12 weeks of age) mice 
were flushed through a 40 or 70 µm filter using RPMI 1640 (10% FBS + 1% 
penicillin/streptomycin) to obtain bone marrow. Cells were spun for 10 minutes at 400 x g at 4°C 
and erythrocytes were lysed using ammonium-chloride-potassium (ACK) lysis buffer (2-3 
mL/mouse, 1-2 minutes at 37°C). After lysis, 5 volumes of media were added to deactivate lysis 
and the cells were spun again, as above. Cells were passed through a filter once more and 
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suspended as 500,000 cells/mL with 20 ng/mL of granulocyte-macrophage colony stimulating 
factor (GM-CSF) (Peprotech). In a 6-well plate, 4 mL (2 million cells) were added to each well 
and the cells were incubated for 5 days at 37°C with 5% CO2. On day 3, 4 mL of media with 40 
ng/mL GM-CSF was added to each well. Cells were scraped and harvested on Day 5 and subjected 
to various treatments. Flow Cytometry verified the cells were >60% CD11c+ and, in agreement 
with recent work describing the heterogeneity of these cells, consisted of 2-3 cell populations that 
varied in CD11b and major histocompatibility complex (MHC) II expression [46, 172, 173]. On 
Day 5, BMDCs were harvested and one million cells were plated in a 6-well plate at a 
concentration of 500,000 cells/mL RPMI (10% FBS). Cells were treated with or without 100 
ng/mL LPS (Sigma L4391, E. coli O111:B4), oleic acid (5 µM), and varying concentrations of 
NO2-OA. Cells were scraped at various time points and either prepared for flow cytometry, 
enzyme-linked immunosorbent assay (ELISA), liquid chromatography coupled with mass 
spectrometry (LC/MS), or western blot after separating cells and media by spinning for 10 minutes 
at 400 x g at 4°C. 
2.3 Human DC Studies 
Human DCs were prepared from frozen CD14+ monocytes purified from peripheral blood 
mononuclear cells (PBMCs) of healthy donors in collaboration with approved protocols under the 
direction of Robert Mailliard, PhD according to standard protocol using MACS® separation with 
CD14 microbeads (Miltenyi Biotec 130-050-201) [174]. Monocytes were thawed and cultured in 
IMDM media with 10% FBS, 2.5% gentamycin, 1000 U/mL GM-CSF (Genzyme NDC 58468-
0180-1) and 20 ng/mL IL4 (R&D Systems 204-IL) for 5 days at a concentration of 500,000 
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cells/mL – creating immature dendritic cells (iDCs). On Day 5, iDCs were activated with a 
combination of LPS, CD40L, and/or IFNγ and treated with 2.5 µM NO2-OA or ethanol control. 
On day 7, cells were harvested for flow cytometry or further activated with J558 cells for 24 hr in 
order to evaluate IL12 production from the media via ELISA.  
2.4 RAW Cell Signaling Studies 
RAW cells (2 million/well in 6 well plate) grown overnight in 10% FBS/DMEM were 
treated with or without LPS (10 ng/mL), 15-oxo-LXA4-Me (25 µM), LXA4 (0.1-25 µM), and 
WRW4 (1 µM) for various time points in 1% FBS/DMEM. Media was collected for ELISA and 
cell lysates were collected for western or PCR analysis. For western analysis, cells were scraped 
into ice cold radioimmunopreciptation assay (RIPA) buffer (150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH = 8) with protease (Pierce) and phosphatase 
inhibitors (Roche). For PCR analysis, cells were scraped into Trizol (Invitrogen). Cytokines were 
measured with ELISA. Vehicle concentrations were kept under 0.3% ethanol. In all antagonist 
studies, cells were treated with WRW4 for 30 minutes prior to treatment. 
2.5 Cell Viability 
For RAW cell studies, cytotoxicity was determined using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay according to the manufacturer’s 
instruction. Cells were plated in a 96 well plate (50,000/well) and treated with 25 µM 15-oxo-
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LXA4-Me and LPS (10 ng/mL) for 24 hr. Viable cells convert substrate into a product that absorbs 
maximally at 570 nm. The results were compared directly between LPS + vehicle (<0.3% ethanol) 
and LPS + 15-oxo-LXA4-Me as absorbance units. For BMDC studies, viability was determined 
using the Zombie Red Live/Dead stain from Biolegend (423110).  
2.6 Western Blot 
Cell lysates (prepared by scraping into 300 μL RIPA buffer with NuPage Sample Buffer 
and reducing agent) were further ruptured via sonication (30 sec on 30 sec off, repeat 3x, pwr=80-
100, QSonica, 4°C)  and protein was clarified by centrifugation 21,000 x g for 5 min at 4°C. 
Samples were heated 95°C for 5 minutes and 20 μL of each sample was loaded onto a 
polyacrylamide gel (Nupage 4-12%) and electrophoresis was performed for 1-2 hr with 180V. 
Protein was transferred to nitrocellulose at 100V for 1 hr at 4°C. Membranes were washed with 
Tris-buffered saline with tween-20 (TBST) buffer and blocked with either 5% Milk or 5% casein 
in TBST for 1 hr at room temperature. Membranes were washed and primary antibodies were 
added overnight at 4°C. Horseradish peroxidase (HRP)-linked secondary antibodies were added 
the following day, incubated with ECL substrates, and imaged with a Bio-Rad ChemiDoc. Details 






Table 1: Antibody Details 
 
Company Target Primary Dilution Catalog kDa Secondary Dilution 
            
Abcam NQO1 1/5000 ab80588 31 1/6000 
Invitrogen GCLM 1/1000 PA5-26111 30 1/3000 
Enzo Life Sciences HO1 1/1000 ADI-SPA-895-F 32 1/6000 
Sigma ACTIN 1/2000 A4700 42 1/2000 
Cell Signaling NOS2 1/1000 13120 140 1/2000 
2.7 PCR 
Cell lysates were prepared by scraping into 1 mL TRIzol (Invitrogen). RNA was obtained 
per manufacturer instruction and measured using a NanoDrop (Thermo). cDNA was prepared 
according to iScript (Bio-Rad) instructions using 500 ng of purified RNA. Taqman (Applied 
Biosystems) assays and fast master mix were used to analyze gene expression using 250 ng cDNA. 
Primers are listed in Table 2 and relative quantification was calculated using established methods 
[175].  
Table 2: PCR primers 
  
Gene Catalog Reference Number Dye 
        
Actin 4352341E Mm00607939_s1 VIC 
Nqo1 4331182 Mm01253561_m1 FAM 
Ho1 4331182 Mm00516005_m1 FAM 
Gclm 4331182 Mm01324400_m1 FAM 
Tnfa 4331182 Mm00443258_m1 FAM 
Il6 4331182 Mm99999064_m1 FAM 
Nos2 4331182 Mm00440502_m1 FAM 
Mcp1 4331182 Mm00441242_m1 FAM 
Il1b 4331182 Mm00434228_m1 FAM 
 
 29 
2.8 Flow Cytometry 
2.8.1 BMDC Studies 
For each experiment, 2-3 technical replicate wells were combined (2-3 million cells), 
centrifuged, and suspended in PBS at 1-5 million cells/mL. Then, 200 µL was plated onto a 
LegendPlex, V-bottom plate (BioLegend) and spun at 400 x g for 5-10 minutes at 4°C. Zombie 
Red (1:400) was used as the viability stain in the majority of experiments and cells were stained 
for 20 minutes at room temperature. Fluorescence-activated cell sorting (FACS) buffer (2% FBS, 
1 mM EDTA, 0.1% sodium azide in PBS) was added to deactivate the viability stain and cells 
were spun again. Then, Fc Block (anti-CD16/32, BioLegend, 1:100) was added in FACS buffer to 
cells in order to block non-specific immunoglobulin receptors for 20 minutes on ice. After 
spinning, cells were stained in 100 µL for 20-30 minutes on ice with various panels. In all cases, 
pooled BMDCs were used for all single stain and FMO controls. After staining, cells were fixed 
for 20 minutes on ice with Cytofix (BD), washed, and analyzed using a BD Fortessa. At least 
50,000 events were recorded for each sample. The following antibodies were used: CD11c-FITC 
(N418, 1:200, Biolegend), CD11b-BUV395 (M1/70, 1:800, BD), MHCII-APC-Cy7 (IA/IE, 
M5/114.15.2, 1:1600, Biolegend), CD40-APC (3/23, 1:200, Biolegend), CD80-BUV737 (16-
10A1, 1:800, BD), and CD86-PE (GL-1, 1:800, Biolegend). Flow Cytometry experiments were 
performed within the University of Pittsburgh, School of Medicine, Department of Immunology 




2.8.2 Influenza Studies 
Bronchoalveolar lavage fluid (BALF) was collected from mice (1 mL Hanks buffered 
saline solution, HBSS with 30 mM EDTA) and centrifuged 400 x g 10 min at 4ºC. Pellets were 
suspended in ACK lysis buffer for 1 min on ice followed by 800 µL PBS and centrifugation as 
above. Pellets were resuspended in 200 µL PBS and added to a V-bottom plate (BioLegend). 
Spleen cells were harvested in a similar manner and used for single stain and fluorescent minus 
one (FMO) controls. Plates were spun as above and stained with Zombie Aqua (Biolegend, 1:200) 
in 100 µL PBS for 20 minutes at room temperature in the dark. FACS buffer (100 µL) was added 
and cells were spun as above. Fc Block (1:100) was added to all samples in 100 µL FACS buffer 
and set for 20 min on ice. Cells were spun and then stained for 30 min on ice in 100 µL FACS 
with the following antibodies: CD45-BV605 (1:200), CD11b-APC-Cy7 (1:200), CD11c-Pacific 
Blue (1:200), Ly6g-AF700 (1:200), F4/80-PE-Cy7 (1:200), CD4-APC (1:200), CD8-FITC 
(1:200), and CD19-BV421 (1:200) – all from BioLegend. Counting beads (BioLegend) were 
added to the final suspension (25 µL beads/ 175 µL cell suspension) to obtain absolute counts. 
Experiments were performed within the University of Pittsburgh, School of Medicine, Department 
of Immunology Flow Cytometry Core on a BD LSR Fortessa. 
2.9 ELISA 
Instructions were followed for each kit: MCP1 (88-7391-88), TNFα (88-7324-88), IL1β 
(88-7013-77), IL6 (88-7064-88), IL12p70 (88-7121), IL10 (88-7105), and IL23p19 (88-7230) – 
all from Invitrogen. Samples were diluted to be within the linear range of the standard curve. A 
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Bio-Plex mouse cytokine 23-plex (Bio-Rad) was used to measure cytokines from murine BALF 
and analyzed with the Luminex platform.  
2.10 Glutathione (GSH) Adduct Formation 
To form the GSH adduct, GS-15-oxo-LXA4, 10 µM 15-oxo-LXA4-Me was incubated with 
100 µM GSH in 50 mM potassium phosphate buffer (pH = 8) for 1 hr at 37°C [133, 143]. Adducts 
were extracted using solid phase extraction and analyzed with multiple reaction monitoring 
(MRM) 658/308. Relative levels of 15-oxo-LXA4 were quantified by normalizing MRM 349/233 
to LXA4-d5 (MRM 356/114) and 13,14-dihydro-15-oxo-LXA4 (MRM 351/235) in the same 
manner.  
2.11 Lipid Extraction and Liquid Chromatography/Mass Spectrometry 
2.11.1 LC/MS - RAW Cells 
RAW cells were plated as above and treated with 25 µM 15-oxo-LXA4. Media and cell 
lysates were scraped into cold PBS over a time course (0, 0.5, 1, 2, 3, and 6 hr). To 1 mL of cell 
lysate or media, 10 µL of LXA4-d5 (1 µg/mL stock) and 5-oxoETE-d7 (2 µg/mL stock) were added 
as internal standards. To each sample, 4 mL of chloroform:methanol (2:1)  was added, vortexed 
and centrifuged for 10 min at 2800 x g at 4°C. The organic layer was dried under nitrogen and 
solvated in 100 µL methanol the day of analysis. Aqueous layers were subjected to C18 solid phase 
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extraction (Thermo Scientific Hypersep), eluted in methanol, dried, and solvated in methanol for 
further analysis. Samples were analyzed on a 6500+ QTRAP coupled to an Exion LC (Sciex). 
Injections were applied to a Luna C18 column (2x100 mm, Phenomenex) with a linear gradient 
using acetonitrile (0.1% acetic acid) as solvent B and water (0.1% acetic acid) as solvent A. 
Samples were loaded at 20% B and the gradient increased to 80% B over 10 minutes, was held at 
100% B for 2 minutes, and equilibrated at 20% B for 3 minutes at a rate of 0.6 mL/min. LXA4 and 
LXA4-derived metabolites were measured using negative electrospray ionization under the 
following MS conditions: CUR 40, CAD med, IS 4500, GS1 70, GS2 65, Temp 600 °C, DP -80, 
EP -7, CE -17, CXP -7. MS conditions were the same for measuring 15-oxoLXA4 GSH adducts; 
however, MS analysis was run in positive electrospray ionization mode and source temperature 
was set to 550°C. GSH adduct separation took place at a flow rate of 0.25 mL/min and the LC 
gradient was linear starting at 20%B at 5 min and increasing to 98%B at 25 min. The gradient was 
held at 100%B for 2 minutes and equilibrated at 20%B until 35 min. To form GS-15-oxo-LXA4, 
10 µM 15-oxoLXA4-Me was incubated with 100 µM GSH in 50 mM potassium phosphate buffer 
(pH = 8) for 1 hr at 37°C[133, 143]. Adducts were extracted using solid phase extraction and 
analyzed with MRM 658/308. Relative levels of 15-oxoLXA4 were quantified by normalizing 
MRM 349/233 to LXA4-d5 (MRM 356/114) and 13,14-dihydro-15-oxo-LXA4 (MRM 351/235) in 
the same manner. 
2.11.2 LC/MS – BMDCs 
BMDCs for metabolomics experiments were scraped and harvested as above. After 
spinning, media samples were frozen at -80°C and the pellets were washed with cold PBS and then 
lysed in 80% ice cold methanol (0.1% formic acid) with 100 µM of internal standard mix (taurine-
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d4, lactate-d3, alanine-d3, and creatinine-d3). On the day of analysis, 100 µL of media was added 
to 400 µL of 80% methanol/0.1% formic acid with internal standards. Media and lysate samples 
were vortexed for 30 seconds, spun at 21,000 x g for 10 minutes at 4°C and supernatants were 
analyzed using LC/MS. Analyses were performed by untargeted LC-HRMS. Briefly, Samples 
were injected via a Thermo Vanquish UHPLC and separated over a reversed phase Thermo 
Hypercarb porous graphitic column (2.1×100mm, 3.0μm particle size) maintained at 50°C.   For 
the 20 min LC gradient, the mobile phase consisted of the following:  solvent A (0.1% formic acid 
in water) and solvent B (0.1% formic acid in acetonitrile). The gradient was the following:  0-12.0 
min 5% B, to 1000% B, 12.0-15.0 min hold at 100% B, 15.0-15.1100% to 5% B, 15.1-20.0 min 
5%B.  Spectra were acquired on a Thermo IDX tribrid mass spectrometer, using both positive and 
negative ion mode, scanning in Full MS mode (2 μscans) from 70 to 800 m/z at 120,000 resolution 
with an AGC target of 5e4.  Source ionization settings were 3.5/2.6 kV spray voltage respectively 
for positive and negative mode.  Source gas parameters were 20 sheath gas, 10 auxiliary gas at 
300°C, and 4 sweep gas. Calibration was performed prior to analysis using the PierceTM Positive 
and Negative Ion Calibration Solutions (Thermo Fisher Scientific).  Integrated peak areas were 
then extracted manually using Quan Browser (Thermo Fisher Xcalibur ver. 2.7).   
2.12 GPCR Binding Assay 
Human FPR2 was expressed in Sf9 insect cells (Invitrogen) using the Bac-to-Bac 
baculovirus expression system (ThermoFisher). Cell cultures were grown in ESF 921 serum-free 
medium (Expression Systems) to a density of 4 × 106 cells/mL and then infected with the 
baculovirus expressing FPR2. The cells were collected by centrifugation at 8000 x g for 10min 
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after 48 hours. For 35S-GTPγS binding assays, ~200 µg/ml of human FPR2 cell membrane was 
incubated with 200 nM purified Gi protein for 20 min on ice in buffer containing 20 mM HEPES, 
pH 7.5, 150 mM NaCl, 5mM MgCl2, 3 μg/ml BSA, 0.1μM TCEP, and 5μM GDP.  Next, 25 μL 
aliquots were transferred to 225 μL reaction buffer containing 20 mM HEPES, pH 7.5, 150 mM 
NaCl, 5mM MgCl2, 3 μg/ml BSA, 0.1μM TCEP, 1μM GDP, 35 pM 35S-GTPγS and ligands (LXA4 
and 15-oxo-LXA4 at 2 μM, WKYMVm, a peptide agonist of FPR2, at 5 μM ). After additional 15 
min incubation at 25 °C, the reaction was terminated by adding 6 ml of cold wash buffer containing 
20 mM HEPES, pH 7.5, 150 mM NaCl and 5mM MgCl2, and filtering through glass giber prefilters 
(Millipore Sigma). After washing four times with 6 ml cold wash buffer, the filters were incubated 
with 5 ml of CytoScint liquid scintillation cocktail (MP Biomedicals) and counted on a Beckman 
LS6500 scintillation counter. The data analysis was performed using GraphPad Prism 6 (GraphPad 
Software). One-way ANOVA was applied for experimental comparisons. Results are shown as 
mean ± SD from 3 independent experiments. 
2.13 Murine model of influenza infection 
Female, BALB/cJ mice (Jackson, 6-8 weeks old) were infected via intranasal injection (50 
µL) with a lethal dose of PR8 (300 TCID50 = 1.5 MLD50). Sterile PBS was used as vehicle control. 
Mice were weighed daily and euthanized when they lost more than 25% of their original weight 
per IACUC protocol. Treatment begin 4 hr prior to initial infection and continued twice daily 
(every 12 hr). Doses were approximated by using 20 g as average mouse weight and delivering 5 
mg/100 µL (25 mg/kg in glycerol trioleate); however, they were not recalculated each day as the 
mice lost weight. For timeline studies, mice were euthanized via pentobarbital injection followed 
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by cardiac puncture. Tissues were harvested at various days during the infection. Blood was 
collected from cardiac puncture and plasma was obtained by collecting in heparin-laced tubes (to 
avoid premature clotting) and spinning 15,000 x g for 5 min at 4ºC. Then bronchoalveolar lavage 
(BAL) was performed to obtain BAL fluid (BALF) for cytokine and titer determination. The left 
lung was process for flow cytometry and the right lung was divided by lobe and frozen in liquid 
nitrogen.  
2.14 Viral propagation and titer determination 
PR8 was propagated in MDCK cells and titered according to established protocols [176]. 
Infectivity was determined using the dose at which 50% of the cells were infected (tissue culture 
infectious dose (TCID)50). Confluent monolayers of MDCK cells were infected with decreasing 
doses of PR8 in a 96 well plate (n=4 each dose) and infected cells were counted after 4 days of 
culture. Cells were ruled infected or not based on destruction of the monolayer determined with 
microscopy. The dose that results in 50% death in mice (Mouse lethal dose 50, MLD50) was 








2.15.1 Statistics – Lipoxin Studies 
Standard deviation (SD) is shown in all experiments except where box and whisker plots 
are used in which the full range of data is shown with the median. Normality tests (Shapiro-Wilk) 
were performed prior to statistical analysis and non-parametric tests were utilized when abnormal 
distributions were observed. Student’s T Tests were utilized for comparisons between two groups 
while One-way or Two-way ANOVA with multiple comparisons (Tukey’s for 2-way or normally 
distributed 1-way, Sidak’s for non-parametric 1-way) was used for 2 or more variable experiments 
across groups. GraphPad was used for all tests. Experiments were repeated at least three times 
(biological replicates) unless otherwise noted. 
2.15.2 Statistics – BMDC studies 
Shapiro-Wilk normality tests were run to determine if non-parametric or parametric tests 
should be used. In each case, normal or non-parametric (Kruskal Wallis) one-way ANOVA were 
run to determine statistical significance. SD is shown in all graphs unless noted otherwise. Each 






2.15.3 Statistics – Influenza studies 
Survival curve significance was determined using the Log-Rank, Mantel Cox analysis. 
Differences in cytokines and cell populations were analyzed with one-way or two-way ANOVA. 




















3.0 15-oxo-Lipoxin4, an electrophilic metabolite of Lipoxin A4, induces anti-
inflammatory and cytoprotective responses in LPS-treated murine macrophages 
 
Gregory J Buchan, Adolf Koudelka, Veronika Cechova, James P O’Brien, Marina C Sarcinella, 
Mohamad Rawas-Qalagi, Bhupinder Singh, Heng Liu, Steven R Woodcock, Cheng Zhang, Bruce 
A Freeman, and Stacy G Wendell. J Biol Chem, Submitted 11/20/19 
3.1 Introduction 
Inflammation is a process associated with the pathogenesis of virtually every disease [2, 4, 
16].  Most therapies directed towards the inflammatory process are designed to inhibit pro-
inflammatory signaling via inhibition of cytokines, bioactive lipids and other factors. It has only 
been within the last several decades that research has focused on the resolution of inflammation as 
a pharmacological target. Resolution was once thought to be a passive process, but it has since 
been realized that, just as there are key signaling pathways that orchestrate the inflammatory 
response, there are also pathways that regulate resolution. A defect in resolution permits an 
uncontrolled inflammatory response that can lead to tissue damage [83]. Rather than completely 
suppressing inflammation, pro-resolving mediators restore cells and tissue to a homeostatic state 
where inflammation is curbed and repair mechanisms are activated [177]. 
Key regulators of both inflammation and resolution are bioactive lipids including 
prostaglandins, leukotrienes, nitro-lipids, resolvins, and lipoxins. Resolvins and lipoxins, as well 
as protectins and maresins, are di- and tri-hydroxy specialized pro-resolving mediators (SPMs) 
formed from enzymatic oxidation of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) 
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and arachidonic acid (AA) [78]. In fact, lipoxin A4 (LXA4), a trihydroxytetraene lipid derived from 
AA was discovered in human neutrophils and the first to be described in the literature as a SPM 
[178, 179]. LXA4 and its isomer, Lipoxin B4, were observed under inflammatory conditions where 
COX and LOX enzymes were both active and able to sequentially oxidize AA – typically via 
transcellular biosynthesis [180, 181]. Later studies demonstrated that aspirin could also lead to 
lipoxin formation upon acetylation of the COX2 prostaglandin active site to produce 15(R)-HETE, 
which would later be oxidized by lipoxygenases to different isomers of LXA4, the epi-lipoxins 
[182, 183]. These bioactive lipids are mainly thought to signal through G protein coupled receptor 
(GPCR)-dependent pathways to promote and resolve inflammation [184].  
Since the early 1980’s, many cell culture and preclinical studies have demonstrated the 
pharmacological effects of LXA4 to inhibit inflammation and promote resolution. Nearly 40 years 
of research has shown that LXA4 can dampen inflammation in a variety of in vivo disease models 
including: acute lung injury, asthma, subarachnoid hemorrhage, acute renal failure, and cancer [87, 
185-191]. Consequently, LXA4 reinvigorated targeting the resolution of inflammation (rather than 
its prevention) for diseases defined by aberrant inflammation; thus promoting the discovery and 
characterization of a variety of novel, lipid mediators that reduce inflammation and promote tissue 
repair and protection [82, 192-195].  
Despite massive success in animal models of disease, LXA4 is yet to be FDA-approved as 
a therapeutic for any inflammatory disorder and has not seen comparable success in clinical trials 
[196-198]. A possible reason for this may be the understudied pharmacokinetics of LXA4. Since 
the discovery of LXA4, only 7 studies examined the metabolism of these species in vitro and even 
less performed any detailed, pharmacokinetic profile in animal models [165, 199-204]. A primary 
metabolite of LXA4 is 15-oxo-LXA4, which is formed through the action of 15-
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hydroxyprostaglandin dehydrogenase (15-PGDH). 15-PGDH is best known for the oxidation of 
prostaglandin E2 (PGE2) to 15-oxoPGE2 and 15-hydroxyeicosatetraenoic acid (15-HETE) to 15-
oxoeicosatetraenoic acid (15-oxoETE) [144, 205]. Similarly, 15-PGDH oxidized the hydroxyl 
group at the C15 position in LXA4, resulting in the formation of 15-oxo-LXA4, which has been 
previously described as an inactive product [165].  
Importantly, both 15-oxoPGE2 and 15-oxo-LXA4 contain an α,β-unsaturated ketone moiety 
that renders these metabolites electrophilic. An abundance of literature has clearly demonstrated 
that electrophilic lipids, including 15d-PGJ2, 11- and 15-oxoETE, nitro-lipids, and DMF (a non-
lipid, α,β-unsaturated ketone) have biological activity that promotes anti-inflammatory signaling 
primarily through GPCR-independent signaling [116, 143, 144, 148, 166, 206-208]. Electrophilic 
lipids signal through Michael addition adduct formation with reactive, nucleophilic cysteines that 
can be found in redox regulatory transcription factors and enzymes NF- ĸB and Nrf2 [116, 131, 
134, 143, 209]. Herein, we demonstrate that 15-oxo-LXA4 is a bioactive metabolite of LXA4 that 
promotes GPCR-independent, anti-inflammatory signaling, in LPS-activated macrophages.  
3.2 15-oxo-LXA4-Me is rapidly metabolized to 15-oxo-LXA4 and retains its 
electrophilic properties 
15-oxo-LXA4-Me pharmacokinetics was first evaluated in vitro at the same concentration 
used in subsequent studies (Fig 6). The methyl ester derivative is quickly converted to 15-oxo-
LXA4 within cells, likely via intracellular esterases, as shown by the appearance of 15-oxo-LXA4 
and the emergence of the reduced product, 13,14-dihydro-15-oxo-LXA4. Most of 15-oxo-LXA4 is 
metabolized, extruded from the cell, or adducted to proteins or small molecular weight thiols (due 
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to Michael Addition) within the first 6 hours after administration (Fig 6A). Glutathione adducts 
were also detected in the media (Fig 7), providing further evidence that 15-oxo-LXA4 is 
electrophilic after release from the methyl ester derivative. Together, these data demonstrate that 
addition of the methyl ester derivative (15-oxo-LXA4-Me) is sufficient to yield 15-oxo-LXA4. 
Finally, I show 15-oxo-LXA4 is electrophilic (same molecular weight and retention time as 










Figure 6: 15-oxo-LXA4-Me is rapidly metabolized to 15-oxo-LXA4 and retains its 
electrophilic properties 
25 µM 15-oxo-LXA4-ME was added to RAW cells (murine macrophages) and incubated for the 
indicated time. Cell media and lysate was collected and prepared for LC/MS analysis.  Free 15-
oxo-LXA4 was measured in cell lysate (A) and media (B). The reduced metabolite of 15-oxo-
LXA4, 13,14-dihydro-15-oxo-LXA4 was also measured over time in both cell lysate (C) and media 
(D). Relative amounts were calculated by dividing the peak area for each analyte by that of the 





Figure 7: 15-oxo-LXA4-Me is rapidly metabolized into 15-oxo-LXA4 and forms glutathione 
adduct 
Chromatogram for 12 hr media sample from the pharmacokinetic study in Fig 6 and prepared 
standard. The dotted line tracing represents profile of a standard made by reacting GSH and 15-
oxo-LXA4-Me in phosphate buffer. The solid line tracing represents the 12 hr media sample. Inset 
displays the MRM transition shown in the chromatogram along with the proposed point of 
fragmentation (bold line). MRM 658/308 represents formation of the GSH adduct (GS-15-oxo-
LXA4) with subsequent cleavage of GSH. Overlapping peaks at 9.35, 9.53, 9.75, and 10.15 min 





3.3 15-oxo-LXA4 inhibits LPS-induced inflammation 
Murine macrophages were treated with LPS (10 ng/mL) with or without 15-oxo-LXA4-Me 
and the degree of inflammation was measured by evaluating the expression and protein production 
of IL6, MCP1, TNFα, IL1β, and inducible nitric oxide synthase (NOS2) over time (Fig 8). As 
expected, LPS induced the expression and production of each cytokine as compared to the 
untreated controls. Pro-inflammatory gene induction was evident at 6 hr and continued through 24 
hr. 15-oxo-LXA4-Me significantly reduced the expression and protein levels of NOS2 (Fig 8A, 
B). Mcp1 mRNA expression was significantly reduced by 15-oxo-LXA4-Me at all times evaluated 
throughout the study; however, protein levels were only significantly reduced after 12 hr post LPS 
administration (Fig 8C, D). Il6 expression was markedly reduced at most time points; however, 
statistically significant reductions were only seen at 18 hr after LPS and 15-oxo-LXA4-Me 
treatment. Results from ELISA demonstrated that there were significant reductions in IL6 at 18 
and 24 hr after LPS administration, but not before hand (Fig 8E, F). There were only significant 
changes in Tnfα expression 12 hr after LPS (Fig 9C). Lastly, Il1β mRNA expression was also 
decreased upon 15-oxo-LXA4-Me from 12-24 hr after LPS treatment (Fig 9B). Finally, there was 
no loss in viability at 24 hr with LPS and 15-oxo-LXA4-Me treatment (Fig 9D). These data show 
that 15-oxo-LXA4 dampens proinflammatory gene expression and cytokine production, consistent 



















Figure 8: 15-oxo-LXA4 represses pro-inflammatory signaling 
25 µM 15-oxo-LXA4-ME was added to RAW cells at the time as 10 ng/mL LPS. Samples were 
harvested at various time points and processed. Relative expression of Nos2 (A), Mcp1(C), and Il6 
(E) mRNA normalized to Actin. (B) Western blot for NOS2 with ACTIN loading control measured 
at 6 and 12 hr after treatment. ELISA data from media for MCP1 (D) and IL6 (F). Two-way 
ANOVA was performed on gene expression and ELISA data, ns = not significant, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Bars represent statistical difference between LPS alone 
and LPS-treated groups. Data were normalized to media no LPS samples. PCR and ELISA data 
are from 3-4 independent experiments with n=4. Western blot is a representative image from three 




3.4 15-oxo-LXA4 activates Nrf2 
We assessed Nrf2 activation by measuring downstream target genes, Nqo1, Gclm, and Ho1 
using PCR (Fig 10). While LPS itself did not induce any expression of the above genes nor their 
protein products, 15-oxo-LXA4-Me indeed increased the mRNA expression of each gene at 
various time points as well as the protein. Nqo1 induction via 15-oxo-LXA4-Me peaked 12 hr post 
LPS administration and was significantly higher than the control at each time point measured (Fig 
10A). Gclm and Ho1 mRNA expression peaked at 6 hr; however, only early time points (6 hr – 
Ho1; 6, 12 hr – Gclm) were significantly higher than the control group (Fig 10C, E). To further 
validate induction of each gene, protein levels were evaluated using western blot. NQO1, HO1, 
and GCLM were all higher than control groups when compared with 15-oxo-LXA4-Me-treated 
groups (Fig 10 B, D, F). Together, these results demonstrate the ability of 15-oxo-LXA4 to induce 
Nrf2-dependent proteins that are involved in cellular repair and recovery during and after 
inflammation. 
Figure 9: 15-oxo-LXA4 represses pro-inflammatory signaling (supplement to Fig 8) 
Full western blot images for NOS2 and ACTIN (in Fig 8) (A). Boxes represent the images shown 
in Fig 8. PCR data for the mRNA expression of Tnfa and Il1b (B, C). Western blot data are 
representative of three independent experiments. Absorbance values from MTT assay (n=3, three 
independent experiments) (D). PCR data are representative of 3-4 independent experiments with 



















Figure 10: 15-oxo-LXA4 induces Nrf2 signaling 
25 µM 15-oxo-LXA4-ME was added to RAW cells at the time as 10 ng/mL LPS. Samples were 
harvested at various time points and processed. Relative mRNA expression (normalized to Actin) 
of Nqo1 (A), Gclm (C), and Ho1 (E). Western blot for NQO1 (B), GCLM (D), and HO1 (F) with 
ACTIN loading control measured at 6 and 12 hr after treatment. Two-way ANOVA was 
performed on gene expression, ns = not significant, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Bars represent statistical difference between LPS alone and LPS + 15-oxo-LXA4-
Me-treated groups. Data were normalized to media no LPS samples. PCR data are from 3-4 
independent experiments with n=4. Western blot is a representative image from three 




3.5 Pro-resolving actions of 15-oxo-LXA4 are FPR2-independent 
Western blot analysis with antibodies from two different companies showed that FPR2 was 
present within RAW cells (Fig 12A). Next, a GPCR activity assay was completed to evaluate the 
ability of 15-oxo-LXA4-ME to bind FPR2, compared with LXA4 and the positive control, 
WKYMVm peptide (Fig 12B). Both LXA4 and 15-oxo-LXA4-ME showed minimal FPR2 binding 
compared to WKYMVm peptide (Fig 12B). Then, murine macrophages were treated with the 
FPR2 antagonist, WRW4 (1 µM), for 30 minutes prior to LPS and 15-oxo-LXA4-ME 
administration in order to inactivate FPR2. Nrf2 target genes were induced upon 15-oxo-LXA4-
ME treatment; however, this induction was not reduced with WRW4 addition (Fig 12C, D). The 
mRNA expression of Mcp1 and Nos2 were once again decreased with the addition of 15-oxo-
Figure 11: Full western blots for Fig 10 
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LXA4-ME and not altered upon treatment with the FPR antagonist (Fig 12F, G). In line with the 
gene expression data, 15-oxo-LXA4-Me-induced changes in protein levels of NQO1, GCLM, 
HO1, and NOS2 were all unaltered with WRW4 treatment (Fig 12E). These data show that, despite 
being a weak agonist for FPR2 compared to WKYMVm, 15-oxo-LXA4-ME can activate Nrf2-



















Figure 12: Signaling actions of 15-oxo-LXA4 are FPR2-independent 
25 µM 15-oxo-LXA4-ME was added to RAW cells at the time as 10 ng/mL LPS. Samples were 
harvested at various time points and processed. Various cell lysates (non-treated) were used for the 
western blot for FPR2 antibodies (A). GPCR response assay (B). Expression of Nrf2 target genes, 
Nqo1 and Ho1 normalized to Actin (C, D). Western blots for Nrf2 target proteins, NQO1, GCLM, and 
HO1 (E). mRNA expression of Nos2 (F) and Mcp1 (G). Western blot of NOS2 (E). Gene expression 
data are the combined results of 3-4 independent experiments (n=4). Western blot analyses are 
representative of 3 independent experiments. -/+ represent the addition of FPR2 antagonist, WRW4 (1 
µM). NS = not significant, **** = p<0.001 between vehicle LPS and 15-oxo-LXA4-ME +LPS groups. 




3.6 LXA4 does not affect LPS-induced inflammation or Nrf2 activation 
Unexpectedly, LXA4 was unable to repress LPS-induced inflammation nor induce Nrf2 
target gene expression within RAW cells in this study (Fig 14). Gene expression data for Ho1 and 
Nos2 (representative of Nrf2 and NF-ĸB pathways, respectively) at 6 hr post LPS/LXA4 
Figure 13: Supplement blots for Figure 12 
Full western blot images are shown for Fig 12 with the outline representing the image shown 
within the figure.  
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administration was analyzed and no changes were seen with addition of 1 µM LXA4 (Fig 14A, B).  
Western blot analysis at 12 hr corroborated gene expression data, showing no changes in HO1 or 
NOS2 protein expression (Fig 14C). These results illustrate that in my model of LPS-induced 
activation of murine macrophages, LXA4 neither activates Nrf2 nor inhibits pro-inflammatory 
responses. In fact, these actions are elicited through the primary metabolite of LXA4, 15-oxo-LXA4 










Figure 14: LXA4 does not affect LPS-induced inflammation or Nrf2 activation 
25 µM 15-oxo-LXA4-ME or 1 µM LXA4 was added to RAW cells at the time as 10 ng/mL LPS. The 
FPR2 antagonist, WRW4 was added 30 minutes prior to treatment and media was replaced. Samples 
were harvested at various time points and processed Gene expression data for Ho1 (A) and Nos2 (B), 
6 hr after administration of 1 µM LXA4 and LPS. Western blot showing protein levels of HO1 and 
NOS2 12 hr after 1 µM LXA4 and 10 ng/mL LPS addition (C). Gene expression data are combined 
from two independent experiments. Western blot images are representative of two independent 





There is increasing evidence to support that targeting inflammation with compounds that 
dampen (rather than inhibit) various pro-inflammatory pathways can be beneficial for many 
disease states including acute lung injury, various autoimmune disorders (e.g. MS and asthma), 
and infection [87, 170, 192, 194, 210-219]. This “fine-tuning” of the host response 
(immunomodulation) offers increased therapeutic potential over global suppression from agents 
Figure 15: Full images for Fig 14 
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like corticosteroids and highly specific inhibitors (e.g. TNFα monoclonal antibodies) by hitting 
multiple targets involved in inflammation (e.g. polypharmacology) without ablating regulatory 
roles of an individual cytokine and/or cell signaling cascade [123]. DMF is a prime example of an 
immunomodulatory compound that targets multiple proteins (likely through cysteine alkylation), 
reducing the production of IL12 and IL23, as well as the recruitment of cytotoxic T cells in models 
of MS [37, 61, 166, 170, 213, 220, 221]. Together, it is clear that modulating immunity, without 
specific (GPCR-dependent) or global suppression (i.e. corticosteroids), has substantial potential 
for treating many inflammatory disorders.  
During inflammation, electrophilic lipids are formed through enzymatic and/or reactive 
oxygen or nitrogen species-dependent mechanisms. For example, prostaglandins can be 
metabolized into electrophilic, α,β-unsaturated ketones (e.g. 15d-PGJ2, 15-oxoPGE2) through 
enzymes like 15-PGDH, and conjugated linoleic acid (cLA) can be nitrated in vivo to form the 
anti-inflammatory signaling mediator, nitro-cLA [116, 148, 222, 223]. 11-HETE and 15-HETE 
(derived from AA oxidation) can also be oxidized into 11-oxoETE and 15-oxoETE, respectfully, 
from 15-PGDH [143, 144, 206]. Likewise, LXA4 is oxidized by 15-PGDH to form 15-oxo-LXA4, 
an electrophilic, α,β-unsaturated ketone [165]. Despite the structural similarities between 15-oxo-
LXA4 and other AA-derived electrophilic lipids, including 15d-PGJ2 and 15-oxoETE, the 
bioactive signaling abilities of 15-oxo-LXA4 have not been critically examined. This study 
provides evidence that 15-oxo-LXA4, but not LXA4, can reduce LPS-induced inflammation in a 
murine macrophage cell line.  
The primary metabolite of LXA4 is oxidized to form 15-oxo-LXA4, which was thought to 
be biologically inactive. However, the biological activity of 15-oxo-LXA4 was only tested in one 
study (deemed inactive) in 2000 and has not been revisited [165]. Herein we demonstrate that 
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although 15-oxo-LXA4 does appear to bind FPR2 (Fig 12B), the receptor responsible for LXA4 
activity, it promotes anti-inflammatory signaling through activation of the Nrf2-mediated 
antioxidant response and inhibition of LPS-driven pro-inflammatory signaling despite FPR2 
inhibition (Fig 12C-G). 15-oxo-LXA4 contains an α,β-unsaturated ketone moiety, conferring 
electrophilic signaling properties that are comparable to other AA metabolites such as 11- and 15-
oxoETE, cyclopentanone prostaglandins, DMF, and nitro-lipids [116, 120, 147, 165]. These 
molecules also signal through GPCR-independent mechanism by forming reversible covalent 
Michael addition adducts with nucleophilic cysteines in redox regulatory transcription factors and 
enzymes [114, 119, 224]. Similar to other electrophilic lipids, 15-oxo-LXA4 formed a glutathione 
adduct (Fig 7). Four prominent peaks with similar retention times (9.35, 9.53, 9.75, 10.15 min) 
between the adduct detected in cell media and a prepared 15-oxo-LXA4-GS standard were 
observed, providing further evidence that 15-oxo-LXA4 is electrophilic after release from the 
methyl ester derivative. Detection of a glutathione adduct as well as 15-oxo-LXA4 and its reduced 
metabolite, 13,14-dihydro-15-oxo-LXA4 (Fig 6) confirm the methyl ester releases the expected 
product in vitro and suggest it 15-oxo-LXA4 is electrophilic.  
15-oxo-LXA4 reduced LPS-induced inflammation, but did not abolish total signaling (Fig 
8). Both gene expression and protein levels of multiple pro-inflammatory cytokines (IL1β, IL6, 
MCP1) and NOS2 were significantly reduced at various time points during LPS-induced activation 
of a murine macrophage cell line in the presence of 15-oxo-LXA4 (Fig 8). However, TNFα 
production was not inhibited with 15-oxo-LXA4 like the other cytokines (Fig 9). Together these 
data demonstrate 15-oxo-LXA4 is active and can significantly lower aspects of LPS-induced 
inflammation without completely abolishing cytokine production. Importantly, LXA4 was unable 
to dampen LPS-induced NOS expression or activate Nrf2, reinforcing the fact that these anti-
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inflammatory effects were due to its electrophilic metabolite, 15-oxo-LXA4 (Fig 14). These data 
corroborate the findings of other studies using electrophilic lipids to mitigate aspects of 
inflammation. The prostaglandin metabolite, 15d-PGJ2 is highly efficient at reducing cytokine 
production and pro-inflammatory gene expression in both cell and animal models [113, 142, 222, 
225, 226]. Another group of studies demonstrated that 15-oxoETE will reduce pro-inflammatory 
cytokine production in both murine and human macrophage/monocyte cells lines [143, 144]. 
Moreover, DMF (recently approved for MS as Tecfidera), an electrophilic fumarate analog, 
inhibits the generation of pro-inflammatory cytokines as well as NOS2 activity [213, 227]. The 
key and common factor between all of these electrophiles is their ability to minimize collateral 
damage from aberrant immune responses without inhibiting the normal function of immunity – 
highlighted when 15d-PGJ2 is used to rescue mice from influenza-induced lung injury without 
impacting viral clearance [225]. Future studies will need to evaluate the role of 15-oxo-LXA4 in 
vivo.  
The activation of Nrf2 and its downstream target genes (e.g. NQO1, HO1, GCLM) results 
in antioxidant production, detoxification, and aids cells in returning to homeostasis after 
undergoing various stressors [86]. Many electrophiles, such as nitro-alkenes and α,β-unsaturated 
ketones will alkylate KEAP1 cysteines, resulting in Nrf2 nuclear translocation and the activation 
of the antioxidant response element [145, 228]. 15-oxo-LXA4 greatly enhanced Nrf2 activity (Fig 
10). The mRNA expression of Nqo1, Gclm, and Ho1 were significantly enhanced by 15-oxo-LXA4 
at multiple time points after LPS administration (Fig 10). In corroboration with gene expression 
data, protein levels of each Nrf2 target gene were clearly induced by 15-oxo-LXA4 at 6 and 12 hr 
after treatment (Fig 10B, D, F). Again, LXA4 had no impact on HO1 (Fig 14). The ability to 
activate Nrf2 antioxidant responses seems to be another common attribute to electrophilic lipids. 
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The nitro-alkenes are highly efficient Nrf2 activators and are in phase II clinical trials for their 
ability to protect cells from injury and dampen inflammation [134, 145]. Many of the salient 
functions of DMF have been attributed to Nrf2 activation [169, 170, 227]. In fact, the Nrf2 an NF-
ĸB pathways interact to regulate inflammation – linking the function of electrophilic lipids to core 
signaling mediators of immunity [93]. Finally, the cellular effects of pro-resolving lipid mediators, 
like LXA4, mimic electrophilic lipids; however, 15-oxo-LXA4, is the first electrophilic metabolite 
to be studied in the context of immunity. 
Interestingly, both LXA4 and 15-oxo-LXA4 increased FPR2 activity in a similar manner 
that was significantly less than that of the positive control, WKYMVm (Fig 12B). However, the 
ability of 15-oxo-LXA4 to inhibit NOS2 and activate Nrf2 target gene expression and protein 
production was not decreased when cells were pretreated with an FPR2 antagonist (Fig 12). 
Moreover, LXA4 was unable to alter NOS2 or Nrf2 target genes to the same extent of 15-oxo-
LXA4 (Fig 14). These results suggest there may be FPR2-independent effects of 15-oxo-LXA4 
and its role in binding FPR2 needs to be examined further.  
In conclusion, the electrophilic metabolite of LXA4, 15-oxo-LXA4, was able to activate 
Nrf2 and inhibit LPS-induced inflammation in RAW cells, a common in vitro model of 
inflammation. Moreover, LXA4 did not mimic any of these changes, suggesting that 15-oxo-LXA4, 
a metabolite previously thought to be inactive, may be responsible for some of its pro-resolving 
properties. In fact, many of the pro-resolving properties attributed to LXA4 and other SPMs greatly 
overlap with electrophilic lipids (e.g. NF-ĸB inhibition and Nrf2 activation) – illustrated in Fig 16. 
Future studies need to address the metabolism of LXA4 and better characterize the levels of 15-
oxo-LXA4 in addition to evaluating the pro-resolving properties of 15-oxo-LXA4. A better 
characterization and delineation of the anti-inflammatory and tissue repairing effects of both LXA4 
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and 15-oxo-LXA4 needs to occur with other pharmaceutical and genetic models to separate the 
FPR2-depedent and alkylation-dependent actions of each lipid. Finally, other electrophilic 
metabolites are formed when pro-resolving mediators are added in vivo; however, nothing is 
known of their activity or tissue concentration. For example, 8-oxoRvD1 and 17-oxoRvD1 (from 
RvD1), and 18-oxoRvE1 (from RvE1) have all been detected, but not well characterized [229, 
230]. A better understanding of pro-resolving mediator metabolism, along with the function of 
their electrophilic metabolites, will better inform the lipid community of their importance in pre-












Figure 16: Schematic representation of LXA4 and 15-oxo-LXA4 signaling 
 LXA4 is oxidized into 15-oxo-LXA4 by 15-PGDH during inflammation. LXA4 is thought mainly 
to signal by binding to the GPCR, FPR2 and intiating a variety of responses (red oval) that result 
in anti-inflammatory and cytoprotective actions. 15-oxo-LXA4 and other electrophilic lipids 
alkylate key regulatory proteins (blue oval) by forming a Michael adduct between the electrophilic 
carbon (marked with the asterisk on 15-oxo-LXA4) and a nucleophilic cysteine. Many of the 
implicated pathways overlap between LXA4 and 15-oxo-LXA4 (highlighted in purple) and elicit 
physiological responses that maintain cellular homeostasis after an inflammatory response. 
Cytokine production and tissue repair were analyzed in this manuscript so they are marked with 
an asterisk, while the other need to be evaluated in future studies. 
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4.0 Nitro-oleic acid inhibits dendritic cell function 
Gregory J Buchan, Veronika Cechova, Adolf Koudelka, James P O’Brien, Renee Anderko, 
Madeline Ellgass, Steven J Mullett, Robbie B Mailliard, Bruce A Freeman, Stacy G Wendell. J 
Immunol – In preparation. 
4.1 Introduction 
Autoimmune diseases are difficult to treat due to their complexity and pervasive disruption 
of the immune system. Typically, self-recognition by T and B lymphocytes is aberrant and tissue 
destruction can result. For example, in MS, effector T cells recognize peptides composing the 
myelin sheath, resulting in breakdown of this protective layer and nervous system complications 
[24]. In systemic lupus erythematosus, loss of self-tolerance leads to the production of auto-
antibodies, forming immune complexes that result in tissue injury [231]. Other autoimmune 
diseases include psoriasis, rheumatoid arthritis, and scleroderma– all of which involve a loss in 
tolerance, and abnormal activation of T and B lymphocytes. The pathogenesis of many chronic 
and autoimmune diseases is caused by irregularities in DC function that culminate in aberrant 
lymphocyte responses. 
Recently, DMF was approved by the FDA for the treatment of MS (Tecfidera®) [166, 232]. 
DMF contains an electrophilic, α,β-unsaturated ketone and alkylates cysteine residues on various 
proteins as well as small molecular weight thiols (i.e. GSH) [61, 166, 208]. Known targets of DMF 
include C150/152 (mouse/human) of GAPDH [61], Cys151 of Keap1, Cys13 of IRAK4, and 
Cys75 of adenosine deaminase [166, 213]. Despite the promiscuity of DMF, it causes profound 
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changes in immune responses and ultimately, decreases DC and T cell activation, which is thought 
to be the reason for its success in treating MS and psoriasis. A successful therapeutic that forms 
covalent adducts is remarkable since these types of remedies have been ignored for decades 
because of their off-target and non-specific effects (e.g. many are used for chemotherapy and are 
highly toxic). However, recent strides have been made in identifying electrophile-sensitive targets 
and many “soft” electrophiles, such as DMF, that are generally non-toxic and possess 
immunomodulatory properties [117, 119, 233, 234]. Recent developments have also lauded the 
electrophile, itaconate for its potential in treating aberrant inflammatory disease [228, 235, 236]. 
In fact, several reviews have emerged describing the anti-inflammatory and tissue-repairing 
abilities of many electrophiles [116, 233, 237, 238]. More specifically, nitro-oleic acid (NO2-OA), 
is currently in Phase II clinical trials for pulmonary hypertension as well as kidney disease 
(PRIMEx and FIRSTx). However, not much is known regarding NO2-OA impact on DC function, 
a key component of most immune responses and auto-immune disorders. 
We hypothesized that NO2-OA, much like the electrophile DMF, would limit DC 
activation and function. Here we show that, NO2OA efficiently limited DC activation at 
concentrations more than tenfold less than DMF. Common surface markers of activation, in 
addition to cytokine and chemokine production, were all decreased with the addition of NO2-OA 
in LPS-activated DCs. Together, these data suggest that NO2-OA rewires DC signaling to a passive 
state, likely through its ability to reversibly alkylate multiple proteins. These results implicate NO2-
OA is a suitable therapy for MS and other auto-immune disorders. Moreover,  these suggest a 
common mechanism between other electrophiles, such as DMF, in modulating 
immunometabolism to confer their effects. 
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4.2 NO2-OA does not impact GM-CSF-induced DC formation 
Bone marrow derived monocytes were differentiated into BMDCs with GM-CSF (20 
ng/mL) for 5 days. Oleic acid (a non-electrophilic control) or NO2-OA were added at the same 
time as GM-CSF at a concentration of 5 µM on day 0. The surface phenotype was analyzed on 
day 5 (Fig 17). No significant differences were seen in viability (Fig 19A) and the percentage of 
CD11c+ cells remained the same among the treatment groups (Fig 19B). Moreover, the CD11b 
and MHCII distribution (Fig 17A-C, Fig 19C) were similar with or without lipid treatment and 
surface expression of CD80 and CD86 were unaltered (Fig 17D, E; Fig 19D, E). The gating 
strategy for this and subsequent experiments is shown in Fig 18. Recent studies have shown 
CD11c+ cells differentiated from bone marrow consist of macrophages, monocytes, and DCs; 
therefore, CD11c+CD11b+MHCII+ were deemed as DCs for their expression of CD80 and CD86 
[46, 173]. These data demonstrate that NO2-OA does not alter the GM-CSF-induced differentiation 
of monocytes into DCs. 
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Figure 17: NO2-OA does not inhibit GM-CSF induced DC differentiation 
Bone marrow derived monocytes were treated with 20 ng/mL GM-CSF with or without  5 µM 
oleic acid or 5 µM NO2-OA. On day 5, cells were collected and analyzed via flow cytometry. 
CD11c+ cells were characterized according to CD11b and MHCII expression with 
CD11b+MHCII+ cells deemed as DCs (Full gating shown in Fig 18). Cells were treated with 
vehicle (A), 5 µM oleic acid (B), or 5 µM NO2-OA (C). CD11c+ CD11b+ MHCII+ DCs were also 
evaluated for CD80 (D) and CD86 expression (E).  
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Figure 18: Gating Strategy 
Cells were gated after excluding doublet populations and dead cells with the viability dye, Zombie 
Red. Then, CD11c+ cells were selected and BMDCs were characterized as 
CD11c+CD11b+MHCII+. The CD11c+CD11b+MHCII- population likely consists of macrophages 
and undifferentiated monocytes. 
 70 
 
4.3 NO2-OA inhibits LPS-induced DC activation 
BMDCs were activated with 100 ng/mL LPS in the presence or absence of oleic acid (5 
µM) or varying levels of NO2-OA for 6 and 24 hr (Fig 20). The gating strategy is the same shown 
in Fig 18. It should be noted that during LPS-induced activation, there were no changes in the 
distribution of CD11c+ cells (Fig 22, 23). Indeed, NO2-OA had no impact on the percentage of 
Figure 19: Supplement to Fig 17 
Viability measured with Zombie Red dye (A). Percentage of Living, CD11c+ cells (B). Percentage 
of CD11c+CD11b+MHCII+ BMDCs (C). Median fluorescent intensity for CD80 (D) and CD86 
(E) of BMDCs.  
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CD11c+ cells at 6 or 24 hr (Fig 23). As expected, LPS did activate immature DCs as evidenced 
by a shift in MHCII (Fig 22A, B) and increases in CD40, CD80, and CD86 at both time points 
(Fig 20, 21).  These data reinforce recent studies that show part of the CD11c+ population (MHCII-
) are likely macrophages or undifferentiated monocytes [45, 46, 173]. LPS-induced activation was 
evaluated by analyzing surface expression of CD40, CD80, and CD86 – markers typically 
associated with DC activation. The surface phenotype of CD40 was decreased at 6 hr after 
administration with statistically significant changes with 2.5 and 5 µM NO2-OA (Fig 20A, D). 
Likewise, 5 µM NO2-OA significantly inhibited the expression of CD80 and CD86 with trending 
decreases in 1 and 2.5 µM (Fig 20 B, C, E, F). However, the decreases at 6 hr post LPS 
administration were not sustained as there were no significant decreases in any marker 24 hr after 
treatment (Fig 21A-F). It should be noted that decreases in viability were observed when 5 µM 
NO2-OA was used and both 6 and 24 hr after treatment but 2.5 µM NO2-OA or below did not alter 
viability (Fig 23A, B). Therefore, for the rest of the chapter, only 2.5 µM NO2-OA results are 
shown. Although there was a loss in viability at 5 µM, there was a dose-dependent trend of 
inhibition at lower concentrations. These data demonstrate that NO2-OA inhibits CD40, CD80, 









Figure 20: NO2-OA inhibits LPS-induced DC activation 6 hr after treatment 
On day 5, BMDCs were treated simultaneously with 100 ng/mL LPS with or without lipid 
treatment for 6 hrs. Cells were then collected and analyzed via flow cytometry. DCs were evaluated 
6 hr after treatment based on CD40 (A, D), CD80 (B, E), and CD86 (C, F). **p<0.01, ***p<0.001 
(normal, One-way ANOVA), $p<0.05 (Non-parametric, One-way ANOVA). Histogram data are 
representative of 4 independent experiments while MFI data are the combined percentages of those 











Figure 21: NO2-OA does not inhibit surface marker activation 24 hr after treatment 
On day 5, BMDCs were treated simultaneously with 100 ng/mL LPS with or without lipid 
treatment for 24 hrs. Cells were then collected and analyzed via flow cytometry DCs were 
evaluated 24 hr after treatment based on CD40 (A, D), CD80 (B, E), and CD86 (C, F). Histogram 
data are representative of 4 independent experiments while MFI data are the combined percentages 












Figure 22: NO2-OA does not alter cellular distribution during LPS treatment 
GM-CSF-differentiated monocytes were activated with LPS and treated with increasing doses of 
NO2-OA. The percentage of BMDCs, characterized as CD11c+CD11b+MHCII+ cells was not 
altered with treatment with the non-electrophilic OA control, nor NO2-OA (B-F).  
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4.4 NO2-OA limits cytokine production during DC activation 
DCs were activated with LPS and simultaneously treated with NO2-OA. Similar to the 
activation surface phenotype of BMDCs, NO2-OA inhibited an array of cytokines at 6 and 24 hr 
post treatment in a dose-dependent manner (Fig 24, 25). Pro-inflammatory cytokines IL6, and 
IL1β, and were significantly decreased with 6 hr of treatment after LPS-induced activation (Fig 
Figure 23: Supplement to Fig 20-22 
Viability was measured at 6 (A) and 24 hr (B) after NO2-OA and LPS treatment with Zombie Red 
viability dye. The percentage of CD11c+ cells are shown for 6 and 24 hr treatments (C, D). The 
percentage of CD11c+CD11b+MHCII+ (BMDCs) for 6 (E) and 24 hr (F) treatments. *p<0.05, 
***p<0.001, One-way ANOVA. Results are combined from 4-5 independent experiments.  
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24A, B). Moreover, DC-specific inflammatory cytokines IL12 and IL23 were reduced to near non-
detectable levels compared to vehicle controls (Fig 24D, E). Unexpectedly, IL10, typically 
classified as anti-inflammatory, was also decreased upon NO2-OA treatment (Fig 24C). Most of 
these changes were sustained for up to 24 hr (Fig 25) with the exception of IL1β, which was no 
longer decreased at the later time point (Fig 25A). MCP1 was unaltered at both 6 and 24 hr (Fig 
24F, 25F). Together, these data show that NO2-OA inhibits several pro-inflammatory cytokines 
during LPS-induced DC activation. Importantly, DC-specific activation cytokines, IL12p70 and 
IL23, were inhibited while inhibition of the other cytokines could be from changes in macrophages 
or undifferentiated monocytes remaining in culture. Lastly, NO2-OA did not completely suppress 




















Figure 24: Cytokine generation is decreased after 6 hr NO2-OA administration 
On day 5, BMDCs were treated simultaneously with 100 ng/mL LPS with or without lipid 
treatment for 6 hrs. Media was then collected and frozen for analysis. ELISA analysis at 6 hr 
post treatment evaluated the level of IL1β (A), IL6 (B), IL10 (C), IL12p70 (D), IL23p19 (E), 
and MCP1 (F). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Data are from 3-4 





4.5 NO2-OA increases Nrf2 activity and inhibits NOS2 in BMDCs 
Nrf2 activation was measured indirectly through the induction of NQO1, HO1, and GCLM. 
Interestingly, NO2-OA induced HO1 3 hr after treatment (FIG 26A); however, NQO1 and GCLM 
were not detected. NQO1 and GCLM were induced 24 hr after treatment, compared to vehicle 
controls (Fig 26C, D). The increase in HO1 was sustained 24 hr after treatment but the vehicle 
group also induced HO1 as compared to the no LPS control (Fig 26B). Lastly, NOS2 was inhibited 
24 hr after treatment with NO2-OA (FIG 26E). These data suggest NO2-OA can activate Nrf2-
depedendent responses in BMDCs as well as inhibit NOS2 induction. Importantly, these results 
are consistent with the effects of NO2-OA and other electrophilic lipids in many cellular and animal 
models of inflammation [113, 131, 140, 142-145, 147, 148, 155, 157, 222, 225, 239-246]. 
Figure 25: Cytokine generation is decreased after 24 hr NO2-OA administration 
On day 5, BMDCs were treated simultaneously with 100 ng/mL LPS with or without lipid 
treatment for 24 hrs. Media was then collected and frozen for analysis. ELISA analysis at 6 hr 
post treatment evaluated the level of IL1β (A), IL6 (B), IL10 (C), IL12p70 (D), IL23p19 (E), 
and MCP1 (F). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Data are combined from 3-4 




Figure 26: NO2-OA activates Nrf2 and inhibits NOS2  
On day 5, BMDCs were treated simultaneously with 100 ng/mL LPS with or without lipid 
treatment for 3-24 hrs. Cells were then collected and frozen for analysis. At 3 hr after treatment, 
HO1 expression was measured with western blot (A). HO1 (B), NQO1 (C), GCLM (D), and NOS2 
(E) were analyzed 24 hr after treatment. Images are representative of 2-3 independent experiments. 
Full blots are shown in Fig 27. 
 82 
 
Figure 27: Full western blot images for Fig 26 
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4.6 NO2-OA alters DC metabolism 
Metabolomics analysis was performed on both lysate and media samples of DC cultures 
treated with or without LPS and NO2-OA. Amino acids, citric acid cycle, and glycolytic analytes 
were measured and normalized to internal standard values (Fig 28). At 12 hr after treatment, 
lactate, succinate, and itaconate were all increased with LPS; however, NO2-OA had no impact on 
their intracellular levels (Fig 28A-C). Interestingly, glutamate was decreased in cellular lysate 
when comparing vehicle and NO2-OA groups that had been activated with LPS (Fig 28D). 
Moreover, citrulline production was significantly decreased with NO2-OA treatment, alluding to 
NOS2 inhibition (Fig 28E). DCs and macrophages rely on aerobic glycolysis during activation 
and this process is partially regulated by Nrf2 and NF-κB [15, 61, 101, 102, 247]. These data 
suggest that NO2-OA does not directly alter aerobic glycolysis through lactate or succinate levels; 
however, changes in glutamate and citrulline may contribute changes in DC activation. 
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4.7 Human DC IL12 production is limited by NO2-OA treatment 
Human DCs (HuDCs) were activated with either LPS or CD40L with or without IFNγ and 
then treated with 2.5 µM NO2-OA. Interestingly, there were no significant differences between 
vehicle and NO2-OA-treated groups for immature (iDC) or LPS/CD40L-stimulated DCs (Fig 29); 
Figure 28: NO2-OA alters DC metabolism 
On day 5, BMDCs were treated simultaneously with 100 ng/mL LPS with or without lipid 
treatment for 12 hrs. Cells were then collected and frozen for analysis. LC/MS analysis evaluated 
intracellular levels of lactate (A), succinate (B), itaconate (C), glutamate (D), and citrulline (E). 
****p<0.0001 One-way ANOVA. SD is shown and data is from one experiment (n=6). The 
cittrulline in non-LPS treated groups was not detectable.  
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However, IL12 production from DCs activated with LPS/CD40L plus IFNγ was decreased in the 
NO2-OA-treated group. These data demonstrate that decreases in DC activation caused by NO2-
OA may be translated to human DCs. Furthermore, NO2-OA-dependent inhibition of DC 
activation may be dependent on IFNγ signaling.  
 
4.8 Discussion 
DCs act as messengers between innate and adaptive immunity by detecting pathogens and 
tissue damage and presenting this signal to T and B lymphocytes [35, 248]. Upon activation, DCs 
will also exert their own defenses against inflammatory stimuli and alert innate immune cells 
Figure 29: HuDC IL12 production is limited by NO2-OA. 
HuDCs were activated with LPS or CD40L with or without IFNγ and IL12p70 was 
measured from the media with ELISA. LPS data is combined from two independent 
experiments using two sets of DCs derived from different donors (n=5-6) while the 
CD40L data is from one experiment (n=3). **p<0.01, ***p<0.001 – normal, two-
way ANOVA with multiple comparisons. 
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through the production of RS and pro-inflammatory cytokines like IL6, IL12, IL23, and IL1β [29, 
249, 250]. At the center of an immune response, DCs are prime targets for therapeutics in a myriad 
of inflammatory diseases, including multiple sclerosis, influenza infection, and cancer [19, 23, 24, 
251, 252]. In fact, DMF, an electrophilic α,β-unsaturated ketone, was recently approved for the 
treatment of MS and is known to limit DC activation, likely through the combination of altered 
metabolism, inhibition of NF-ĸB, and Nrf2 activation [37, 61, 96, 112, 166, 167, 170, 253, 254]. 
Electrophilic nitro-fatty acids limit inflammation at least in part to NF-ĸB inhibition and Nrf2 
activation [133, 134, 145, 147]. Herein, we show evidence supporting that NO2-OA, an exemplary 
nitro-fatty acid, inhibits DC activation. These results offer new insights into how nitro-fatty acids 
function in animal and human models of inflammatory disease as well as suggest a common role 
of electrophilic lipids to manipulate DC function.  
To begin, BMDCs were harvested and matured in a manner similar to recent studies, 
confirming GM-CSF-induced CD11c+ cells are heterogenous (Fig 17) [46, 173]. There are clearly 
multiple CD11c+, CD11b+, MHCII+ “DC” populations when mouse bone marrow cells are 
differentiated for 5 days with GM-CSF (Fig 17A-C, Fig 18). In this study, BMDCs populations 
were defined as CD11c+, CD11b+, MHCII+ population for all flow cytometry experiments 
involving surface marker expression. NO2-OA did not alter the cellular composition of GM-CSF-
induced DC culture (Fig 17A-C). Moreover, NO2-OA did not inhibit CD80 or CD86 expression 
in CD11c+CD11b+MHCII+ cells (referred to as DCs for the rest of the article, Fig 17D, E). Lastly, 
viability of GM-CSF-induced DCs was not impacted when NO2-OA was added at the same time 
as GM-CSF (day 0 and day 3, Fig 19 A).  
Next, the surface phenotype of LPS-activated DCs was evaluated upon NO2-OA treatment 
(Fig 20-23). There were no significant differences in the cellular composition 
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(CD11c+CD11b+MHCII+) of DCs with increasing concentrations of NO2-OA or the non-
electrophilic lipid control, oleic acid (Fig 22, Fig 23A-F) at 6 or 24 hr after LPS administration 
and treatment. Although there were no significant differences between CD80, and CD86, decreases 
in CD40 expression were observed at 6 hr post LPS administration in CD40 with 2.5 NO2-OA. 
The significant decreases of CD80 and CD86 at 5µM NO2-OA may be attributed to a loss in 
viability of surrounding cells, but there were clear, dose-dependent trends in each marker (Fig 
20A-F). However, all changes in surface marker phenotype were not sustained at 24 hr after 
treatment (Fig 21A-F). Together, these data suggest that NO2-OA alters DC activation in a time-
dependent manner without changing maturation. 
DCs are primary responders to both DAMPs and PAMPs. Activation of DCs result in the 
production of pro-inflammatory cytokines in addition to RS. In corroboration with surface 
phenotype, NO2-OA decreased the production of multiple cytokines (Fig 24, 25). Most cytokine 
levels were significantly decreased at 6 hr after treatment with 2.5 µM NO2-OA while only IL6, 
IL12p70, and IL23p19 remained dampened at 24 hr (Fig 24, 25). The decreases observed with 
1µM NO2-OA were not statistically significant; however, they may suggest a dose-dependent 
response. TNFα levels were not altered with either concentration of NO2-OA (data not shown). 
Together, these data provide evidence to support the claim that NO2-OA can inhibition DC 
activation and signaling. Other lipid electrophiles such as 15d-PGJ2 affect immune cells in a 
similar manner as well as the non-lipid electrophile, DMF, suggesting a common role amongst 
electrophiles to modulate immunity [37, 113, 142, 148]. 
The major antioxidant and cellular repair pathways mediated via Nrf2 signaling are 
becoming more important in the context of controlling inflammation [93, 103, 104, 255]. Many 
electrophilic lipids (e.g. 15-oxoETE, 15d-PGJ2, nitro-fatty acids) are known activators of Nrf2 and 
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the non-lipid electrophile, DMF is FDA-approved treatment for MS (Tecfidera®) [38, 114, 134, 
143, 148, 161, 256]. This study is the first to show NO2-OA activates Nrf2 signaling in DCs (Fig 
26). HO1 is induced as early as 3 hrs and NQO1 and GCLM are activated later and their levels are 
sustained for at least 24 hr (Fig 26). Moreover, NOS2 was inhibited 24 hr after treatment, 
suggesting NF-ĸB activity was suppressed (Fig 26E). These changes are consistent with a decade 
of studies in other cellular and animal models using NO2-OA to decrease aspects of inflammation 
[116]. Changes in DC activation, along with Nrf2 activation and NOS2 inhibition, motivated an 
evaluation into DC metabolism, which is central to function. 
Immunometabolism of macrophages and DCs is a rapidly growing field [47, 48, 51, 257]. 
Importantly, novel therapeutics are being designed to target the increased anaerobic metabolism 
that contributes to inflammation and cancer [258-261]. DMF was approved for treating MS and 
recent studies show that it can partially reverse the metabolic changes that accompany 
inflammation [61]. Furthermore, alterations in NF-ĸB or Nrf2 signaling can impact cellular 
metabolism [15, 101, 102, 106, 236]. DC metabolism was analyzed and LPS induced increases in 
lactate, itaconate, and succinate in DCs, confirming previous studies (Fig 28A-C) [262-265]. 
Interestingly, while NO2-OA did not decrease lactate, succinate, or itaconate levels, glutamate and 
citrulline were decreased upon administration (Fig 28). A decrease in glutamate may signify a 
change in the glutamate/cystine transporter (xCT) that is regulated by Nrf2; however, future tests 
need to understand this further and measure glutathione and cystine levels [266, 267]. Changes in 
glutamate metabolism may effect DC activation in addition to downstream changes in T cell 
interactions, which need to be explored further [267, 268]. Decreases in citrulline verify a decrease 
in NOS2 expression; although, nitric oxide levels need to be analyzed in future studies to confirm 
inhibition in DCs.  
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Lastly, human DC IL12 production was also decreased with NO2-OA suggesting this 
electrophilic lipid can play a role in human immunity (Fig 29). Interestingly, changes were only 
observed when cells were activated with both LPS and IFNγ in human DCs whereas significant 
changes were seen with only LPS in the murine DCs. Therefore, the role of NO2-OA in IFNγ 
signaling will need to be further explored.  
Future studies will examine the different CD11c+ cells subsets by sorting according to 
CD11b and MHCII and evaluate surface marker expression, cytokine production, and cellular 
metabolism in these specific subsets. This study analyzed early (6 hr) and late (24 hr) time points 
for flow and cytokine studies; however, more detailed, temporal analyses need to be performed, to 
better understand the sequence of cell signaling that occurs between NF-ĸB, Nrf2, and cellular 
metabolism. Lastly, T cell activation with or without DC involvement needs to be evaluated in the 
presence of NO2-OA and will be the focus of future experiment. In conclusion, NO2-OA is an 
effective inhibitor of DC activation and lays the groundwork for understanding the mechanism of 











5.0 Electrophilic lipids attenuate influenza pathogenesis 
5.1 Introduction 
Influenza A viruses (IAV) impose a significant burden on global health and economy. 
More than 250,000 deaths worldwide are reported annually and yearly costs attributed to IAV 
infection exceed $10 billion in the United States alone [269, 270]. Re-assortment of IAV’s 
segmented genome and an error-prone RNA-dependent RNA polymerase increase the occurrence 
of mutations, promoting more facile zoonosis (e.g. H7N9, H5N1) and human-human transmission. 
Unlike seasonal IAV infection, severe IAV infection, from pandemic or zoonotic IAV strains, are 
resistant to tetravalent vaccines and antiviral agents [271, 272]. Furthermore, the incidence of 
highly pathogenic H7N9 avian influenza,  omnipresent in migratory birds and poultry, led to over 
650 deaths in 2013 and continues to pose a pandemic threat to humans [273, 274]. There have been 
four pandemics in the past century beginning with the 1918 Spanish Flu (H1N1) resulting in over 
40 million deaths [269, 274, 275]. Pandemic IAV strains strongly promote pro-inflammatory 
cytokine and RS generation, leading to higher mortality than seasonal strains due to dysregulated 
inflammation (Fig 30) [276]. Lung injury occurs in response to neutrophil infiltration of the 
alveolar space, oxidative damage, and edema from disrupted tight junctions, leading to acute 
respiratory distress syndrome [16, 276-280]. Current strategies to alleviate the burden of IAV are 
not effective against pandemic strains and no drug strategies target the exacerbated host response 





IAV is a segmented, negative stranded RNA orthomyxovirus that transcribes its genome 
in the nucleus [274, 284]. IAV stimulates both cytoplasmic (e.g. RIG-I, NLRP3) and endoplasmic 
(e.g. TLR3) pattern recognition receptors, leading to the production of cytokines and chemokines 
via nuclear factor kappa B (NF-ĸB) and interferon (IFN) response factors, igniting the innate 
immune response [285-290]. Viral proteins (e.g. hemagluttinin, HA) also play a role in perturbing 
the host-response. HA can overload translation machinery causing endoplasmic reticulum stress 
and production of RS [291, 292]. Basic polymerase (PB1-F2) and acid polymerase (PA-X) 
contribute to cell death and altered redox state in host cells [293-297]. Furthermore, Non structural 
protein 1  undermines the IFN response [298-300], with mutations in any one of these proteins 
increasing virulence [301]. Continual activation of the innate immune response from host and viral 
factors leads to a positive feedback response that enhances cytokine expression, RS production 
and infiltration of leukocytes promoting lung injury by evoking cell death, protein oxidation, and 
Figure 30: NO2-OA can mitigate viral pathogenesis. 
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damage to epithelial barriers [16, 275-277, 287, 302-306]. In severe cases (e.g. pandemics, elderly 
infection) these insults can lead to acute respiratory distress syndrome [277-279, 307]. Therefore, 
immunomodulatory agents that target an overwhelming host response have been gaining attention 
[308]. Examples include cyclooxygenase 2 (COX2) inhibitors [309, 310], suppression of RS 
generation [269, 282, 311-314], NOS2 inhibition [315], direct inhibition of NF-κB activation [316-
319], and Nrf2 activation [320-323]. Electrophilic lipids broadly impact inflammation by 
covalently modifying regulatory proteins responsible for both propagating (e.g. NF-κB) and 
limiting (e.g. Nrf2) inflammatory injury [116, 145]. Due to a pleiotropic nature conferred by a high 
reactivity with functionally-significant cysteine moieties that regulate the transcriptional programs 
regulated by NF-κB and Nrf2, an electrophilic lipid-based therapeutic strategy designed to limit 
IAV-induced lung injury has strong merit. 
NF-ĸB-mediated gene expression is inhibited via mechanisms involving Michael addition 
of the electrophilic fatty acid with nucleophilic Cys target residues [140, 164, 324, 325]. This in 
turn inhibits the expression of enzymes responsible for RS and lipid mediator release (e.g. NOS2 
and COX2) and suppression of pro-inflammatory mediator expression (e.g. TNFα, MCP-1, IL-6) 
[116, 154, 164, 326-330]. Under basal conditions, Nrf2 is bound by Kelch-like ECH-associated 
protein 1 (Keap1), ubiquinylated, and degraded by the proteasome [331]. Keap1 Cys alkylation by 
electrophilic lipids induces Nrf2 release and subsequent nuclear translocation, where Nrf2 
activates ARE-regulated expression of many cytoprotective proteins [145, 332]. Consequences of 
electrophilic lipid-mediated Nrf2 activation include increased a) biosythesis of GSH, b) expression 
of the antioxidant enzymes superoxide dismutase (SOD) and catalase and expression of the 
cytoprotective proteins NQO1 and HO1 [332]. Notably, the electrophilic lipid, NO2-OA, decreases 
expression of the NF-ĸB target gene products TNFα, IL-6, and MCP1 [164, 333] and increases 
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Nrf2 target gene products NQO1 and HO-1 [145, 330, 334]. Other endogenous electrophilic lipids 
such as 15-oxoETE and 15d-PGJ2 also activate Nrf2 and inhibit NF-ĸB via the same mechanisms 
[143, 164, 324]. Because of pleiotropic signaling properties, electrophilic lipids have the potential 
to abate the lung injury caused by an overzealous host response to IAV (Fig 30). 
The synthetic electrophilic lipid, NO2-OA, simultaneously activates Nrf2 and inhibits NF-
ĸB signaling, has passed pre-clinical toxicology/pharmacokinetics testing following five FDA-
approved early stage human safety/efficacy trials of both intravenous (IND 122583) and oral (IND 
124524) formulations. Affirmation of Nrf2 and NF-ĸB pathway engagement in healthy obese 
humans also came from these Phase 1 trials. Lead drug candidates are now being evaluated by the 
Pitt-based Complexa, Inc. in FDA-approved Phase 2 trials in chronic lung and renal disorders. The 
experiments herein tested more acute applications of this lipid electrophile-based new drug 
strategy, with the objective of quickly translating pre-clinical studies into viable therapeutic trials. 
Electrophilic lipid-targetable pathways are critical in the pathogenesis of pandemic (pdmH1N1) 
[319, 321]. Excessive RS generation is associated with severe IAV pathogenesis and acute lung 
injury. In fact, suppression of the oxidant-producing enzymes NOX, NOS2, COX2, and XO 
increased survival in animal models [279, 309, 310, 312, 313, 315, 335-339]. Furthermore, 
alterations in redox state (e.g. via oxidative stress) are also attributed to enhanced IAV replication 
and GSH analogs were used to restore the reducing environment of epithelial cells [143, 292, 340-
343] and decrease viral gene expression [292, 343-345]. Leukocyte infiltration, lung injury, and 
exacerbated cytokine production are associated with increased mortality and severe IAV infection, 
and are being evaluated as therapeutic targets [16, 19, 225, 279, 280, 304, 346-351]. Nrf2 
activation strategies are also protective in cell models of IAV infection [320, 321] due to increased 
SOD, catalase and HO-1[352-355] and preservation of a reducing environment within cells by 
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increased expression of enzymes of GSH synthesis. Inhibition of the NF-ĸB signaling cascade 
limits several aspects of the IAV-induced adverse immune response since NF-ĸB is a key regulator 
of NOS2, COX2, and cytokine and chemokine production. The electrophilic lipid, 15d-PGJ2 
rescued mice from lethal IAV; however, its mechanism of action in the context of its electrophilic 
nature was not discussed [225]. Importantly, ablation of pro-inflammatory and RS-generating 
systems does not always negatively impact the host’s ability to clear virus. Knockdown of type I 
IFN receptor paradoxically results in increased survival of mice infected with IAV [350, 356], and 
the same occurs with decreasing NOS2 or COX2 [309, 310, 339]. I hypothesized that electrophilic 
lipids will mitigate IAV-induced lung injury by promoting antioxidant responses and limiting 
inflammation.  
5.2 Oral administration of NO2-OA increase mouse survival during lethal influenza 
infection 
Mice were infected with a lethal dose of influenza and treated with 25 mg/kg NO2-OA, 60 
mg/kg oseltamivir phosphate (Tamiflu), or vehicle control twice daily for 5 days after the infection 
starting 4 hr prior to infection (Fig 31A). Weight loss is shown as a percentage of original weight 
(Fig 31B). Remarkably, survival was significantly increased with NO2-OA treatment (Fig 31C). 
Moreover, increases in survival were not accompanied with any significant changes in viral titer 
measured in BALF (Fig 31D). Together, these data show that NO2-OA can improve mouse 





Figure 31: NO2-OA increases survival of mice infected with lethal dose of influenza. 
Female, Balb/cJ mice were infected with 300 TCID50 PR8, treated twice daily for 5 days after infection, and 
monitored for weight loss over time. Treatment regimen consisted of vehicle (glycerol trioleate), 60 mg/kg 
Tamiflu, or 25 mg/kg NO2-OA (A). Weight loss (B) and survival (C) data are combined from two independent 
experiments (n=10). BALF titer is from a separate experiment in which mice were sacrificed on days 2, 4, 6, and 
8 (n=5) in order to track viral load over time (D). SD is shown for weight loss and viral load. Significance for 
the survival study was determined using Log-rank (Mantel-Cox) test where p=.0092 between vehicle and NO2-
OA-treated groups (**).  
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5.3 NO2-OA administration decreases cytokine production during influenza 
infection without completely suppressing immune responses 
Cytokine responses were measured from BALF on days 2, 4, 6, and 8 after the infection 
(Fig 32, 33). No significant changes were seen in any cytokine measured 2 days after infection 
(Fig 32, 33). On day 4, GCSF and MCP1 were significantly decreased (Fig 32G, I). Many changes 
were observed on day 6 including significant decreases in the production of IL4, IL10, IL12p70, 
MIP1β, TNFα, Eotaxin, MCP1, GM-CSF, G-CSF, and IFNγ (Fig 32A-I, 33F). Decreases in 
MIP1β, Eotaxin, and MCP1 were also observed 8 days after infection (Fig 32D, F, G). However, 
total suppression of cytokines did not occur since there was never a change in IL1β, MIP1α, or 
RANTES (Fig 33A, B, D). In fact, KC levels were increased on day 6 along with increases in KC, 
IL6, and IFNγ on day 8 (Fig 33C, E, F). Together these data suggest that NO2-OA dampens 
inflammatory cytokine production during influenza infection without total suppression of the 














Figure 32: NO2-OA decreases cytokine production during severe influenza infection. 
Female, Balb/cJ mice were infected with a lethal dose of influenza (PR8 – 300 TCID50) and 
treated with 25 mg/kg NO2-OA. Mock infected mice were given an intranasal injection of sterile 
PBS and vehicle mice were infected with PR8 and treated with glycerol trioleate. Treatment lasted 
5 days and the dotted line in each graph represents the last day of treatment. BALF cytokines were 
measured and harvested on day 2, 4, 6, and 8 (n=5). Results are from one experiment. Significance 







Figure 33: NO2-OA cytokine effects do not result in total suppression of immune response. 
Female, Balb/cJ mice were infected with a lethal dose of influenza (PR8 – 300 TCID50) and treated 
with 25 mg/kg NO2-OA. Mock infected mice were given an intranasal injection of sterile PBS and 
vehicle mice were infected with PR8 and treated with glycerol trioleate. Treatment lasted 5 days 
and the dotted line in each graph represents the last day of treatment. BALF cytokines were 
measured and harvested on day 2, 4, 6, and 8 (n=5). Results are from one experiment. Significance 




5.4 NO2-OA decreases T cell recruitment without altering total cell count 
Immune cell populations were analyzed from mouse BALF via flow cytometry on various 
days after infection and treatment (Fig 34-37). The gating strategy for innate immune cells is 
shown in Fig 34, 35. Living leukocytes (CD45+) cells were further gated according to CD11c and 
CD11b expression in order to distinguish myeloid and lymphoid subsets (Fig 35). Myeloid cells 
(CD11b+) consisted of mostly neutrophils (Fig 35D) along with TNFα and NOS2 producing DCs 
(TipDCs) (Fig 35D). It should be noted that without further markers (e.g. F4/80, Ly6c) these 
populations cannot be truly separated from interstitial macrophages and other inflammatory 
monocytes; however, TipDCs are prominent in influenza infection and would be included in this 
population [19, 357]. Lymphoid cells (CD11b- CD11c-) were then divided according to CD4 and 
CD8 expression (Fig 35C). Cells negative for CD11b, CD11c, CD4, and CD8 were then stratified 
with CD19 to identify B cells and possibly NK cells; however, CD49b would need to be included 
in future studies to validate NK populations (Fig 35E). It should also be noted that CD4 and CD8 
populations are likely T cells but need further validation with CD3.  
There were no differences in absolute cell count between vehicle and NO2-OA-treated 
groups until 8 days after infection (Fig 36B, C, 37A). This change may be a reflection of significant 
decreases in both CD4 and CD8 T cells with the addition of NO2-OA (Fig 36H, I, 37D, E). 




Figure 34: Gating strategy for influenza studies. 
Granularity and size of cell populations are shown by SSC x FSC 
(A). Beads are highly fluorescent in ever channel and were gated 
according to APC and FITC (B) and then removed from 
subsequent analysis. Doublet exclusion based on SSC (C) and 
FSC (D) preceded live/dead analysis using Zombie Aqua (E). 
Living cells were then gated according to CD45 before 
characterizing more specific, leukocyte subsets (F). These data 
are from one experiment, representative of 5 mice per group. 
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Figure 35: Gating strategy for individual leukocytes. 
Living, CD45+ leukocytes (A) were gated according to CD11c and 
CD11b (B). Myeloid negative (CD11c- CD11b-) populations were 
further divided into CD4+ and CD8+ Cells (C). Myeloid cells were 
further divided into neutrophils (Ly6c+) and TipDCs (D). NK cells may 
be the CD19- arising from CD4 and CD8 double negative (DN) cells 




Figure 36: Flow cytometry analysis of cell subsets.  
Gated populations are shown for mock + vehicle, flu + vehicle, and flu + NO2-OA. Gating by 
CD11c x CD11b (A-C). Neutrophil and TipDC populations are shown (D-F). Pseudocolor plots 








Figure 37: Absolute cell counts. 
Total cell counts were evaluated by using Precision Count Beads (A). Neutrophils (CD11b+ 
Ly6g+), TipDC and other monocyte-derived cells (CD11b+ CD11c intermediate), CD4+ and 
CD8+ (CD11b- CD11c-) were all measured in BALF (B-E). Two-way ANOVA with Tukey’s 
multiple comparisons was used to determine significance where *p<0.05, ****p<0.0001. These 




Influenza infection poses a significant threat to humanity and pathogenic strains (i.e. H5N1, 
H7N9) result in robust inflammatory responses that can lead to acute respiratory distress syndrome 
[20, 358-362]. Viral reassortment (antigenic shift) as well as accumulating mutations (antigen 
drift) in IAV strains make treatment difficult with current vaccine and antiviral strategies [274, 
281, 363-367]. Moreover, excessive inflammation from the immune response is recalcitrant to 
antiviral treatment; therefore, novel strategies that target the host are being explored [212]. 
Examples include blocking TLR4 receptor signaling, activating Nrf2 responses, inhibiting NF-κB, 
and decreasing reactive oxygen and nitrogen species generation [19, 225, 255, 269, 282, 311-313, 
315, 317, 319-321, 323, 336, 351, 352, 355, 368-372].  
Electrophilic lipids, including NO2-OA are known activators of Nrf2 and inhibit NF-κB 
responses [116]. Indeed, NO2-OA increased the survival of mice infected with a lethal dose of IAV 
(Fig 31). Importantly, viral clearance was not affected as shown in the TCID50 measurements in 
Fig 31D. These results are similar to studies using 15d-PGJ2, an electrophilic, α,β-unsaturated 
ketone, to ameliorate severe influenza infection [225]. It should be noted that NO2-OA was added 
4 hours prior to treatment in this model and future studies need to evaluate the efficacy when 
administered multiple days after infection – a time when antivirals become inefficient [338].  
Oral administration of NO2-OA decreased the production of multiple cytokines including, 
GM-CSF, G-CSF, TNFα, IL4, IL10, IL12p70, MCP1, MIP1β, IFNγ, and Eotaxin (Fig 32). 
However, not all cytokines were decreased (Fig 33). There were no changes in MIP1α, RANTES, 
or IL1β (Fig 33A, B, D). Interestingly, IL6 and KC were increased (FIG 33C, E) with NO2-OA 
which is inconsistent with other in vitro and in vivo studies involving NO2-OA [135, 245, 373]. 
Lastly, although IFNγ is decreased on day 6, day 8 levels are increased (Fig 33F). The differential 
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expression of cytokines could be due to the cessation of treatment on day 5. Specifically, in the 
case of IFNγ, it is possible that the effect of NO2-OA peaked around day 5/6 resulting in decreased 
production and then there was a rebounding effect that accounts for the increased production on 
day 8 (Fig 33F). Furthermore, each cytokine is likely regulated in a different manner via 
transcription, synthesis, and degradation – all of which could be affected by NO2-OA to varying 
degrees.  
Unlike a similar in vivo study using a zymosan-induced peritonitis model, NO2-OA 
increased neutrophil recruitment (FIG 37B) [135]. I expected total cell recruitment to decrease in 
addition to neutrophils; however, this did not occur until day 8 with total cell recruitment (Fig 
37A). Surprisingly, CD4+ and CD8+ T cells were significantly decreased with NO2-OA treatment 
(FIG 37D, E). This is the first study to examine T cell recruitment with NO2-OA delivery and I 
propose changes in DC activation are responsible. Although there were no significant changes in 
TipDC recruitment (Fig 37C), decreases in GM-CSF, G-CSF, MCP1, and IL12p70 could lead to 
altered monocyte recruitment, DC maturation and activation – all of which can impact T cell 
recruitment. Better flow cytometry with markers such as Ly6c, F4/80, CD103, CD80, CD40, and 
CD86 would provide more information regarding this proposal.  
These studies were preliminary and need further optimization and analysis. The survival 
data shown here were repeated twice (n=10); however, cytokine and flow cytometry data are from 
one experiment. After these initial experiments, inconsistencies appeared in subsequent studies. A 
third attempt to repeat the survival data showed no significant changes. Further attempts were also 
made to repeat the T cell data but to no avail. These discrepancies could be due to inadequate 
verification of NO2-OA (several different batches across several years). Moreover, freezer issues 
(-80C going down to -20C) resulted in moving IAV stocks between multiple freezers. Although, 
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stocks were propagated and TCID50 measurements were taken, other unknown effects may have 
occurred to the virus (e.g. sequence mutation) that contributed to the above reproducibility issues. 
Small sample size may also be an issue and I may have just observed a gradual regression to the 
mean. I believe that a new cyclodextrin-based delivery of NO2-OA in the water may yield more 
consistent results. Lastly, better batch-to-batch LC/MS analysis needs to occur prior to treatment 



















6.0 Final discussion and future directions 
 
Inflammation is essential to our survival; however, aberrant immune responses contribute 
to a plethora of acute, chronic, and autoimmune diseases [374]. Severe infection, despite current 
antibiotic or antiviral therapies, often leads to irreversible organ damage (e.g. Sepsis, ARDS) due 
to excessive inflammation [20, 215, 287, 375-380]. Chronic inflammation from poor diet can lead 
to atherosclerosis and cardiac failure [3, 4, 15, 381-385]. Finally, autoimmune disorders are 
innately defined by aberrant inflammation – MS is a prime example of DC and T cells destroying 
the myelin sheath [23, 24, 231, 386-388]. Novel therapeutics, that dampen aberrant immune 
responses while maintaining necessary inflammation, are required to combat these diseases. 
Our understanding of electrophilic lipid signaling is growing and it is clear that they are 
efficient immunomodulating agents. Two major classes of electrophilic lipids are the nitroalkenes 
and the α,β-unsaturated ketones – both with the ability to enhance the resolution of inflammation 
in addition to minimizing collateral damage from the original immune response [116, 131]. 
Electrophilic lipids have shown efficacy in a wide variety of inflammatory disease models 
including, acute lung injury caused by influenza infection, pulmonary hypertension, metabolic 
syndrome, and asthma [135, 137, 162, 222, 225, 389-391]. DMF (a non-lipid, electrophilic, α,β-
unsaturated ketone) was recently approved for MS (Tecfidera®) and NO2-OA (CXA-10) is in 
phase II clinical trials for pulmonary arterial hypertension, focal segmental glomerulosclerosis, 
and asthma (PRIMEx – NCT03449524, FIRSTx – NCT03422510, ALMA – NCT03680976). 
Moreover, this body of work, along with many others illustrate that electrophilic lipids are often 
formed in vivo during inflammation and likely play a central role in regulating immune responses 
[114, 115, 135, 392].  
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6.1 15-oxo-LXA4, electrophilic metabolite of lipid mediator, LXA4, is active 
In chapter 3 of this dissertation, the activity of 15-oxo-LXA4, the primary metabolite of 
LXA4, was evaluated. I concluded that 15-oxo-LXA4 was efficient in inhibiting aspects of LPS-
induced activation of a murine macrophage cell line (Fig 8). Furthermore, 15-oxo-LXA4 activated 
Nrf2-dependent target genes (Fig 10). The inhibition of pro-inflammatory gene expression and the 
induction of Nrf2 target genes were independent of the proposed receptor for the parent lipid, 
LXA4 (Fig 12). This was the first study to ever evaluate either LXA4 or 15-oxo-LXA4 in RAW 
murine macrophages activated via LPS. Importantly, these data contradict the one study that 
demonstrated a lack of 15-oxo-LXA4 activity in human neutrophils; however, the minimal 15-oxo-
LXA4 binding to FPR2 is consistent [165]. Differences between studies may be the result of using 
different cell lines but illustrate that further studies need to evaluate both LXA4 and its metabolite, 
15-oxo-LXA4, to better understand their combined pharmacology.  
Demonstrating that 15-oxo-LXA4 is indeed active and, in fact, displays similar anti-
inflammatory and pre-resolving properties of its parent lipid, LXA4, begs the question: to what 
extent can the profound cellular effects of pro-resolving lipid mediators be attributed to their 
electrophilic metabolites? Of the 4 classes of specialized pro-resolving mediators identified 
(Lipoxins, Resolvins, Maresins, and Protectins) and decades of research, less than 10 studies 
measured their electrophilic metabolites, let alone analyzed their potential activity [165, 199, 200, 
204, 230, 393]. Resolvins are further oxidized to 18-oxoRvE1, 12-oxoRvE1, 8-oxoRvD1, and 17-
oxoRvD1 [229, 394]. Interestingly, 8-oxoRvD1 was just as effective as RvD1 in reducing PMN 
infiltration [229]. Furthermore, Maresin is metabolized into 14-oxoMaR1, but only one study 
evaluated its activity and concluded it is inactive [395]. Future studies need to evaluate both the 
electrophilic metabolite and the parent lipid to fully understand the immunomodulatory effects 
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seen in cell and animal studies. In depth LC/MS pharmacokinetics studied need to be performed 
in animal models using pro-resolving lipid mediators to characterize electrophilic lipid formation. 
Lastly, measures need to be taken (e.g. enzyme inhibition, receptor knock-out) to separate the 
effects of the parent lipid and electrophilic metabolite in cell and animal models.  
In regards to 15-oxo-LXA4, other models of inflammation need to be examined to confirm 
its anti-inflammatory and cytoprotective roles in immunity. This study only examined RAW 
macrophages but THP1 (human monocyte) cells are another great introductory model for basic 
inflammation studies. Then, primary cell models (e.g. bone marrow derived macrophages) need to 
be evaluated and finally, animal models can be used to compare 15-oxo-LXA4 efficacy to that of 
LXA4. The challenge in using an animal model will be synthesizing 15-oxo-LXA4 to sufficient 
quantities. Due to their ability to alkylate proteins, bind glutathione, and even incorporate into lipid 
membranes – electrophilic lipids notoriously require higher doses to achieve intracellular 
quantities sufficient to signal [114, 396]. 
In addition to evaluating the major effects of 15-oxo-LXA4 in multiple models of 
inflammation, a deeper understanding of its mechanism of action is required. Many electrophilic 
lipids (e.g. DMF, nitroalkenes) are known to alkylate NF-ĸB and Keap1 resulting in the inhibition 
of pro-inflammatory gene expression and activation of Nrf2, respectfully [116]. No study has 
determined if 15-oxo-LXA4 alkylates proteins in a manner similar to other electrophilic lipids. In 
Fig 7, I demonstrate 15-oxo-LXA4 forms a glutathione adduct; however, further studies can better 
characterize the fragmentation pattern of this species to confirm the adduct is covalent.  Proteomic 
studies after immunoprecipitation experiments may better identify protein targets for 15-oxo-
LXA4 and confirm alkylation events. Moreover, novel click chemistry techniques are evolving that 
may “trap” electrophile-protein adducts, and evaluate them using LC/MS-based proteomics [233, 
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234, 397]. Although the observable effects are very similar, 15-oxo-LXA4 could inhibit 
inflammation through a separate mechanism. Furthermore, genetic models such as Keap1-/- and 
Nrf2-/- could confirm Nrf2 activation seen in this study.  
6.2 NO2-OA alters DC Immunity 
Chapter 4 of this dissertation demonstrated that NO2-OA, an electrophilic nitroalkene, 
inhibits several aspects of DC activation. In addition to the canonical pro-inflammatory cytokines 
(e.g. IL6, MCP1), NO2-OA inhibited the production of IL12p70 and IL23p19, two major cytokines 
linked to DC activation (Fig 24, 25). Moreover, the surface marker expression of CD40, CD80, 
and CD86 was also suppressed upon NO2-OA administration during LPS-induced activation (Fig 
20). This study is in line with similar research that examined nitroalkene pharmacodynamics in 
BMDCs in addition to BMDMs. Myself and colleagues demonstrated that IFN signaling was 
dampened upon treatment with NO2-OA or NO2-cLA in BMDMs stimulated with dsDNA or 
herpes simplex virus [115]. Moreover, IL6 production in BMDCs was decreased with NO2-cLA 
treatment; however, DC-specific cytokines and surface marker phenotype were not evaluated. 
Together these results suggest DC activation is altered by nitroalkenes and they may act as novel 
therapeutics for diseases with a DC component – much like MS. 
The NO2-OA related effects on DC immunity mentioned above are currently attributed to 
a combination of at least Nrf2 activation and NF-ĸB inhibition. Both pathways are critical in the 
regulation of immunity in addition to DC function [99, 398]. The results at the end of this study 
demonstrate that target genes of Nrf2 were indeed activated by NO2-OA (Fig 26). Furthermore, 
NOS2, a gene regulated by NF- ĸB was also inhibited (Fig 26). These results are consistent with 
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other electrophilic lipids such as 15d-PGJ2 and 15-oxoETE [113, 142-144, 147-149, 226].Together 
these data reinforce the fact that electrophilic lipids may, as a class, act as efficient 
immunomodulators and be effective therapeutics for a myriad of inflammatory diseases. However, 
deeper mechanistic understanding is required.  
Assays designed to validate the involvement of NF-κB and Nrf2 are needed. Examples 
include luciferase assays, western blots focused on nuclear translocation, genetic knock-out 
models, and LC/MS proteomic studies to confirm alkylation of each target by NO2-OA. Cytokines 
are regulated by transcription factors other than NF-κB, such as activating protein 1 (AP1), IRFs, 
and PU.1 – none of which have every been directly evaluated during NO2-OA administration. 
Differential targeting of transcription factors, in addition to time of sampling, may explain why 
some cytokines were altered and some were not at 6 and 24 hr. Furthermore, better temporal studies 
(i.e. before 6 hr and in between 6-24 hr) to better understand changes in cytokine production and 
surface marker expression. The same can be said for evaluating DC metabolism. I only looked at 
a few metabolites at 12 hr after treatment – more detailed analyses can be performed early and 
later during treatment. Lastly, a full pharmacokinetic study in DCs needs to take place to 
characterize the metabolism and half-life of NO2-OA. Together, these experiments would add key 







6.3 Electrophilic lipids play a role in viral pathogenesis 
Myself and colleagues from Denmark were the first to demonstrate that viral-induced 
inflammation can result in electrophilic, nitroalkene formation [115]. Several electrophilic, α,β-
unsaturated ketones (e.g. 13-oxoODE, 5-oxoETE) were reported to form during influenza 
infection; however, their electrophilic nature was not discussed [346, 399]. Most viral infections 
induce NOS2 and NOX enzymes that generate reactive oxygen and nitrogen species [22, 370, 
400]. Moreover, during inflammation, cell membranes release unsaturated fatty acids that are 
prone to oxidation and nitration reactions that occur from the reactions described in the 
introduction of this dissertation. Furthermore, hydroxylated fatty acids derived from COX and 
LOX-dependent oxygenation of arachidonic acid and other unsaturated fatty acids are reported to 
form during the resolution of inflammation. Many of these lipids are likely metabolized into 
electrophilic lipids in a similar manner as reported for LXA4 in Chapter 3 of this dissertation. Thus, 
the inflammatory environment is ideal for electrophilic lipid generation and future studies need to 
confirm their formation in a variety of viral infections. 
The formation of electrophilic lipids during viral infection is remarkable because decades 
of studies have shown how these species can manipulate immune responses. In this report NO2-
OA was shown to inhibit cytokine responses and promote mouse survival in a lethal IAV infection 
model (Fig 31-33). Furthermore, Chapter 4 demonstrates how electrophilic lipids can inhibit DC 
activation, which may play a role in decreasing T cell recruitment in the influenza model (Fig 36, 
37). These actions likely result from an accumulation of alkylation events that alter regulatory 
protein function. For instance, NF-κB is a known target for various electrophilic lipids and is 
essential in most immune cell signaling cascades [15, 37, 108, 109, 112, 113]. Nrf2 activation is 
also a target for electrophilic lipid-based alkylation and may regulate NF-κB as well [38, 93, 95, 
 113 
98, 103, 134, 143, 145, 148, 169, 255, 320, 321, 398, 401, 402]. Additionally, electrophilic lipids 
will bind glutathione and can alter the redox state, another important factor in cellular outcome 
during infection [246, 297, 403-405].  
6.4 A word on specificity 
Clearly, a major limitation to studies involving electrophilic lipids is addressing the 
specificity. Gaining a complete knowledge of specificity will be difficult for the following reasons. 
First, hundreds of different proteins have cysteines that have the potential to form Michael adducts 
with electrophilic lipids (let alone histidine or lysine residues that can also be modified). Second, 
the availability of these cysteines will depend on the redox environment of the cell and vary 
according to protein structure and concentration. For instance, the tendency of an electrophilic 
lipid to form a cysteine adduct will depend on the pKa of that particular cysteine [224]. 
Furthermore, as the concentration of proteins change (e.g. NF-κB levels rise and fall during 
immune responses along with Nrf2), it is likely that electrophilic targets will change. The same 
applied to the redox state of the cell, which is highly dependent on GSH concentrations – a prime 
target of Michael adduct formation. Third, each point listed above will change during the course 
of an immune response and is likely cell and tissue-dependent. Lastly, electrophilic metabolism 
will play a role in specificity since some metabolites retain their electrophilicity and may occupy 
protein targets. Therefore, to truly ascertain target specificity, one must perform full detailed, 
temporal studies that analyze 1) GSH/GSSG levels and other aspects of redox state (e.g. 
NADPH/NADP+); 2) pharmacokinetics of the electrophilic lipid via LC/MS, 3) the levels of all 
proteins containing cysteines within the cell (as well as a proteomic analysis of electrophile 
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adducts), and 4) the response being analyzed. This is an extremely (if not impossible) task at this 
point.  
Strides are being made in methods designed to detect protein adducts with electrophiles 
[122, 233, 234, 397]. These techniques, combined with LC/MS-based approaches can begin to 
tease apart mechanisms of action and specificity when combined with other molecular analyses. 
For example, take the LPS-induced activation model above, in RAW cells. A new study can focus 
on the first 6 hr of LPS and NO2-OA treatment by taking samples every 30 minutes. At each time 
point, analyze cytokine production, pro-inflammatory gene and protein expression, GSH/GSSG 
ratio, and electrophile adducts. Each one of these experiments would have to be performed 
independently because you cannot use the same sample for PCR as western blot or for ELISA for 
LC/MS. These types of studies would then have to be carried out for the duration of the immune 
response and in each cell of interest. Only then, can an absolute specificity begin to be addressed.  
6.5 Final remarks 
In conclusion, electrophilic lipids are relevant immunomodulators. These species are 
formed during inflammation, augment immunological responses, bolster cellular recovery, and 
minimize tissue damage. In these studies, I show that a common class of pro-resolving lipid 
mediators (Lipoxins) are metabolized into electrophilic, α,β-unsaturated ketones that contribute to 
their anti-inflammatory and cytoprotective responses. Furthermore, DC activation is inhibited by 
NO2-OA, in addition to other electrophilic lipids, demonstrating these class of potential 
therapeutics can alter both innate and adaptive immunity. Finally, I show how NO2-OA can 
improve the survival of mice in model of influenza-induced acute lung injury. With more 
 115 
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